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ABSTRACT 
Background: Asthma is a major health problem in children and most troublesome during 
severe or persistent symptoms. Children with problematic severe asthma have a 
disproportionate consumption of health care, despite high-dose treatment with inhaled 
corticosteroids (ICS). Little is known about children with impaired asthma control or 
problematic severe asthma in regards to prevalence in a normal population, characterisation and 
classification, and health effects measured as health-related quality of life (HR-QoL).  
Aim: The overall aim of this doctoral thesis was to evaluate the burden of symptoms and 
factors associated with impaired asthma control in schoolchildren.  
Materials and Methods: The study population consisted of 3 015 children up to 12 years of 
age from the prospective birth cohort BAMSE, and children from the Severe asthma study with 
problematic severe asthma (n = 56) and, for comparison, controlled asthma (n = 39). Parental 
questionnaires collected data on environmental exposures, asthma symptoms and treatments. In 
the BAMSE study, asthma control was classified based on parental reports and according to a 
modified GINA classification. The prevalence of severe asthma with dispensed high-dose ICS 
was estimated through the Swedish drug register. Evaluations with component-resolved allergy 
diagnostics, exhaled nitric oxide (FeNO), bronchial hyperresponsiveness to methacholine 
(BHR), blood count of eosinophils and HR-QoL were applied in the Severe asthma study. 
Results: In the BAMSE cohort, a high proportion of children with asthma were classified as 
impaired in their asthma control (partly or uncontrolled) at 8 years, 84% of 323, and at 12 years, 
53% of 329, (p < 0.001). Parental report of symptoms varied in these children, with more 
activity limitation (66% vs. 48%, p < 0.001) and wheeze > 4 times in last year (52% vs. 38%,   
p = 0.002) at 12 years compared with at 8 years, but fewer with nocturnal symptoms (36% vs. 
82%, p < 0.001) and less acute healthcare utilization (15% vs. 34%, p < 0.001) at 12 years. 
Severe asthma was prevalent in 0.4% of children in a normal urban population at age 12, or 4% 
among children with asthma. 
Children with impaired asthma control at both 8 and 12 years in the BAMSE cohort (n = 91) 
and children with problematic severe asthma had more often a family history of allergic disease 
and comorbidity of rhinitis than children with controlled asthma. 
Multi-sensitization to animal-derived components was more pronounced in problematic severe 
asthma than in controlled asthma, 25% vs. 8% (p = 0.03), and was associated with increased 
eosinophil inflammation as compared with children sensitized to fewer animal-derived 
components, FeNO 38 ppb vs. 25 ppb (p = 0.002), blood eosinophils 0.65 vs. 0.39 (p = 0.021), 
and BHR 112 vs. 28 (p = 0.002). 
Children with problematic severe asthma were more impaired in HR-QoL than children with 
controlled asthma 5.4 vs. 6.7 (p < 0.001). 
Conclusion: A high proportion of schoolchildren reported impaired asthma control. Children 
with problematic severe asthma have impaired HR-QoL, with effects of limitations in daily 
activities and reduced emotional well-being. Common factors associated with children having 
impaired asthma control at both 8 and 12 years and problematic severe asthma were family 
history of allergic disease and comorbidity of rhinitis.  
Key words: Asthma control, Children, Component-resolved allergy diagnostics, Health-related 
quality of life, Problematic severe asthma  
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1 INTRODUCTION   
 
Throughout the world, asthma is a common disease, especially in children [1]. The 
pathophysiology of asthma is characterised by airway inflammation and bronchial 
hyperresponsiveness, which subsequently cause symptoms of wheezing, breathlessness, 
chest tightness and coughing [2]. There seems to be a combination of genetic predisposition 
and environmental factors involved in development of asthma symptoms [3-5]. A family 
history of allergic diseases increases the risk for development of sensitization and persistent 
asthma [6, 7], but nevertheless, as a part of the complexity of asthma and other allergic 
diseases, it has been suggested that other non-allergic mechanisms also play a part [8]. 
Demonstration of inflammation in children with asthma symptoms provides support for the 
diagnosis of current asthma [9, 10].  
 
Anti-inflammatory treatment improves symptom control and decreases the risk for 
exacerbations in patients with asthma [11]. According to the Global Initiative for Asthma 
(GINA) a child’s asthma is under control when he or she can play without troublesome 
symptoms or limitations, sleep without awakening from coughing and avoid serious attacks 
or declined lung function [12]. For some the asthma symptoms remit during childhood while 
others have life-long symptoms with health effects. The persistency of symptoms is related 
to underlying severity. The severity is assessed by the patient’s requirement for treatment to 
achieve good control of symptoms [13]. Those who do not respond to standard therapy 
appear to have increased burden of symptoms, disproportional consumption of health care 
[14], and poorer health-related quality of life (HR-QoL) [15]. Asthma severity appears to 
inversely correlate with children’s HR-QoL, including psychological and social wellbeing 
[16]. In clinical practice, measurement of HR-QoL facilitates identification of the children 
with the greatest need for improved asthma treatment. For children with persistent symptoms 
and severe asthma there is an obvious need to improve understanding of poorer response to 
given treatment and asthma care. It has been demonstrated that psychosocial factors in the 
family history have effect on health disparities [17]. The patient’s and caregiver’s abilities to 
understand and follow basic health information are of major importance for treatment of 
chronic diseases such as asthma, and defines the skills of health literacy [18]. For health care 
professionals family limitations in health literacy is a major challenge and requires an 
individualized approach to offer health care based on the children’s and parents’ skills to 
obtain and follow health information.   
 
The clinical guidelines for managing asthma include four essential components of asthma 
care: assessment and monitoring, patient education, control of environmental and 
comorbidity factors that affect asthma, and drug treatment. The aim of this thesis was to 
assess schoolchildren with impaired asthma control and provide knowledge on how to better 
approach these children with asthma care. The present thesis was based on children in two 
different cohorts: the population based BAMSE birth cohort with a longitudinal study design 
and the multi-centre cross-sectional Severe asthma study with a selected material of patients.  
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2 BACKGROUND 
 
2.1 ASTHMA – A GLOBAL HEALTH PROBLEM  
Worldwide, asthma constitutes a major health problem and economic burden [19]. Over 300 
million people worldwide are affected by asthma [20], with great variation between countries 
[21], Figure 1. European studies in schoolchildren estimate an asthma prevalence of 10% 
[22-24]. In recent years the prevalence seems stationary, but increases in Africa, Latin 
America and parts of Asia [25].  
 
 
Figure 1. Prevalence of clinical asthma throughout the world based on doctor’s diagnosis or intake of asthma 
medication [21].  
 
Indicators of increased health cost of asthma like e.g. health utilization, medication and lost 
school/work days are associated with severe and uncontrolled asthma [26]. In undeveloped 
countries with limited economic resources the proportion of severe symptoms seems to be 
much higher than in wealthy countries, despite respiratory symptoms of e.g. current wheeze 
being more common in the wealthy world [27]. In addition, studies have shown that patients 
with lower socio-economic status are associated with more impaired asthma control [28-30], 
and further attention is needed to assist patients with impaired asthma control through better 
management strategies and more effective and cheaper medication.    
 
Literacy can be defined as the skills required for functioning in society, developing 
knowledge and achieving personal and professional goals. Health literacy has been defined 
as the degree to which individuals have the capacity to obtain, process, and understand the 
basic health information and services needed to make appropriate health decisions [31]. 
Asthma care for patients who have limited health literacy has been shown to be very costly 
[32], and is more common in certain groups in the society i.e. ethnic minorities, immigrants 
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and in those with limited education [33]. Adult caregivers with low health literacy are likely 
to exhibit negative health behaviours that affect their children’s health, and the children are 
likely to use more health care [34]. Possible effects of poorer health literacy in children with 
severe asthma remain unknown.  
 
2.2 ASTHMA SEVERITY 
Asthma is presented in different severities. The severity is influenced by the patient’s 
underlying pathophysiology as well as on environmental exposures and trigger factors [6]. 
International guidelines recommend stepwise and standardised asthma treatment. The 
definition of severity is based on the intensity of treatment required for a patient to achieve 
good asthma control [13]. Schoolchildren from 5 years of age have mild asthma if the asthma 
is characterized by clinical improvements on low-dose inhaled corticosteroids (ICS), while 
moderate asthma requires higher doses, up to 400 microgram (budesonide), in combination 
with long-acting beta-2 agonist and/or leukotriene antagonist [35]. Schoolchildren are 
classified with severe asthma on basis of a required high-dose of > 800 microgram 
budesonide or equivalent to achieve symptom control [36, 37]. If control is not possible in 
spite of such high-dose treatment, asthma is classified as problematic severe asthma.    
 
2.2.1 Asthma control 
The ultimate goal for all patients is to achieve asthma control. There are various tools for 
evaluating a patient’s asthma control, one is to use validated questionnaires e.g. Asthma 
Control Test (ACT) or Asthma Control Questionnaire (ACQ) [38, 39], another is to evaluate 
symptoms in patient history based on recommended characteristics from the Global Initiative 
for Asthma (GINA) [12]. These characteristics emphasize optimal asthma control as no 
symptoms, undisturbed sleep, no severe exacerbations, no emergency visits, normal lung 
function and no limitations in daily activities, Table 1. Although the GINA guidelines are not 
validated, the characteristics are widely used as the golden standard for both clinical research 
and for asthma care [40, 41]. Based on a patient’s number of characteristics, GINA classifies 
asthma as controlled, partly controlled or uncontrolled [42]. The GINA guidelines include 
two domains for assessment, the first is the evaluation of symptoms and the second is the 
patient’s future risk for adverse events. Few population-based studies have assessed asthma 
control during childhood with a focus on different age groups. Treatment and diagnosis may 
be affected by how children’s symptoms are presented and likewise occurrence of specific 
symptoms may vary during childhood. 
 
Asthma is, as far as we know, a non-preventable disease in children, often requiring regular 
treatment and health care. The response to treatment differs between patients and the 
underlying reason for that is largely unknown [14, 43]. Factors in patient’s history or 
environment are recognised to worsen or increase the risk for morbidity i.e. sensitization to 
allergens, tobacco smoke, family history for disease and comorbidities [3, 44, 45], Effects of 
psychosocial factors affecting mental health may also have a substantial impact on a child’s 
asthma [46, 47]. The clinical challenge is to support children and caregivers to handle or, if 
possible, solve or avoid critical health factors. Specific factors associated with persistent 
asthma in children are largely unknown. In this thesis, children with severe or persistent 
 4 
symptoms will be compared with children having controlled asthma in order to identify 
relevant factors that can be highlighted and implemented in children’s health care.  
 
 
Table 1. Characteristics and classification of asthma control according to GINA [12]. 
 Controlled Partly controlled Uncontrolled 
A. Characteristics All of the following Any measure presented Three or more features 
of partly controlled 
asthma 
Daytime symptoms None 
(twice or less/week) 
More than 
twice/week 
Limitation of activities None Any 
Nocturnal symptoms/awaking None Any 
Need for reliever/rescue 
inhaler 
None More than twice/week 
Lung function (PEF or FEV1) Normal < 80% predicted or 
personal best (if known) 
B. Future risk assessment ǂ 
ǂ Features that are associated with increased risk of adverse events in the future include: poor clinical control, 
frequent exacerbations in the past year, admission to critical care for asthma, low FEV1, exposure to cigarette 
smoke, high dose medications.
 
Ï
 An exacerbation in any week makes that an uncontrolled asthma week and should prompt review of 
maintenance treatment to ensure that it is adequate. 
 
2.2.2 Severe asthma 
Although most children with asthma respond well to given treatment [11], patients with 
severe asthma appear to be therapy-resistant with an increased risk for exacerbations despite 
high-dose anti-inflammatory treatment [37]. This heterogeneous group of patients suffers 
increased burden of symptoms including lost school/work days, increased health care 
utilization and impaired lung function [19, 48, 49]. Attempts to identify clinical biomarkers 
for predicting the risk of severe asthma or asthma exacerbation have unfortunately failed. 
Paediatric health care requires more knowledge on how to improve the health for children 
with severe asthma. Increased awareness about the burden of symptoms of severe asthma 
and the effect on children’s daily life could facilitate development of health care programs.  
 
There is an obvious need to investigate severe asthma and identify reasons for poor treatment 
response. To reduce the risk for misclassification when analysing this patient group, the 
terminology of severe asthma has been revised during the last decade. Problematic severe 
asthma is an international designation term which is used in the present thesis [50, 51], this 
definition is adapted to countries where treatment is available and affordable. The term 
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‘problematic severe asthma’ refers to first confirming the diagnosis of asthma in children 
[51], and then subdividing children into two different groups, each carrying different health 
messages and challenges. The first level is to identify patients with difficult-to-treat asthma 
according to identified aggravating factors that might explain symptoms e.g. untreated 
comorbidities, poor adherence or environmental factors. For this group it is recommended to 
approach these aggravating factors before applying novel or advanced therapies [50, 52]. 
Such a distinction is important so that side effects of ineffective or unnecessary treatment are 
avoided. The second level is therapy-resistant asthma, which despite long-term, high-dose 
treatment with ICS, is insufficiently controlled, Figure 2. The nomenclature of problematic 
severe asthma has never been approached clinically in patients. The World Health 
Organization (WHO) has also adapted the nomenclature of problematic severe asthma with 
extension to patients in low-income countries having untreated severe asthma due to 
undiagnosed asthma or unavailability of therapy, and for patients which asthma only can be 
maintained only with the highest level of recommended treatment [53]. In this thesis, two 
definitions of severe asthma were approached; in the BAMSE study the WHO definition was 
used for estimation of children with severe asthma in a normal population. The term 
problematic severe asthma was applied in the Swedish Severe asthma study.   
 
 
Figure 2. The term problematic severe asthma refers to confirmation of asthma diagnosis and separates patients 
with difficult-to-treat asthma according to identified aggravating factors from those with severe therapy-resistant 
asthma [50].  
 
The prevalence of severe asthma is largely unknown, although this patient category has 
yielded a lot of research interest in recent years [54-56]. The majority of studies published to 
date have analysed a selected group of patients. A population-based study may improve 
estimation of prevalence and add generalizable information about this morbidity.  
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2.3 ALLERGY  
According to S.G.O. Johansson et al. “Atopy is a personal and/or family tendency, usually in 
childhood or adolescents, to become sensitized and produce IgE antibodies in response to 
ordinary exposures to allergens, usually proteins. As a consequence, these persons can 
develop typical symptoms of asthma, rhinoconjunctivitis, or eczema” [57]. The term atopy is 
thus reserved for describing a person’s genetic predisposition to become IgE-sensitized to 
allergens. Development of allergic symptoms and sensitization is more common in children 
with family history of atopy [58, 59]. Association between asthma and sensitization to 
primary aeroallergens is common in children with asthma [24, 60]. To define allergy in 
children with asthma a positive skin prick test or presence of IgE in serum is required [61]. 
 
The nomenclature describes allergy as a hypersensitivity reaction initiated by specific 
immunological mechanism [57]. Sensitization to allergens is common in schoolchildren with 
asthma [44]. The sensitization starts in the mucosa when antigen-presenting cells uptake 
allergen and present it to naïve T cells, Figure 3. T cells differentiate into Th2 cells and 
induce naïve B cells to switch and become IgE-producing B cells and memory B cells.  
 
IgE-mediated reactions to harmless antigens or allergens induce immunological responses 
and cause immediate allergic symptoms e.g. rhinitis, asthma or anaphylaxis. The immediate 
allergic reaction induces degranulation release of histamine upon allergen cross-linking of 
surface-bound IgE on mast cells and basophils. A late-phase response causing increased 
allergic inflammation occurs at the site of the allergen exposure, initiated by allergen-
presenting Th2 cells. Activated Th2 cells signal for cellular recruitment of eosinophils, 
activated to release inflammatory mediators, chemokines and cytokines.  
Conventional diagnostics of sensitization recommend in vivo use of the skin prick test (SPT) 
[62], or in vitro measuring specific IgE antibodies in serum [63]. In this thesis, a positive 
SPT response or specific IgE antibodies towards any of the tested allergens was designated 
as sensitization. However, traditional diagnostics have limitations in their concordance and in 
the quantification of sensitization [61, 64]. Thus, as extract-based diagnostics contains the 
whole nature of an allergen, various specific IgE antibodies could react to the same single 
allergen, containing different allergenic components. In clinical practice, this poses a 
limitation in determination of patient’s primary sensitization. Component-resolved 
diagnostics (CRD) is a new method for measuring specific IgE towards single allergen 
components in vitro, the measurement can be either singleplex or multiplex, e.g. by using an 
allergen microarray chip [65].
 
The clinical usefulness is under validation, but the main 
advantage of using CRD is that it enables the identification of cross-reactivity or species-
specific components and components associated with mild/local reactions to severe/systemic 
reactions [60, 66-68]. To date, the practical use and identification of clinically relevant 
allergenic components among schoolchildren with problematic severe childhood asthma has 
not yet been proven.  
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Figure 3. Overview of the allergic immune response, with permission from [69]. (A) Sensitization and memory 
of allergen initiated by antigen-presenting cells (e.g. dendritic cells) in mucosa presenting allergen to naïve T 
cells. T cells differentiate into Th2 cells that induces a class switch from naïve B cells to IgE-producing B cells. 
(B) Immediate allergic reaction causing degranulation of mast cells and release of histamine. (C) Inflammatory 
late-phase reaction initiated by allergen-presenting Th2 cells recruiting eosinophils and activating release of 
inflammatory mediators, chemokines and cytokines.  
 
 
On-going exposure to aeroallergens is associated with increased bronchial inflammation and 
risk of exacerbations in severe allergic childhood asthma [70]. In order to define relevant 
strategies for allergen avoidance and treatments, analysed IgE may be used to visualize 
sources of exposure and identify underlying sensitization [71]. Defining sensitization in 
problematic severe asthma is complex, due to extensive multiple sensitizations, and thus the 
protocol recommends the use of several diagnostic methods in children with problematic 
severe asthma [72].  
 
2.4 HEALTH-RELATED QUALITY OF LIFE 
For the purpose of collecting valuable information about the patients’ own perceived health, 
validated questionnaires of health-related quality of life (HR-QoL) could be used. The broad 
definition of HR-QoL covers different aspects and dimensions of health. By agreement this 
includes general health, physical functioning, physical symptoms, emotional functioning, 
cognitive functioning, role functioning as well as social wellbeing and functioning [73]. 
Since there is a wide variation of aspects, different instruments address quality of life in 
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different ways. There are some generic instruments which cover several aspects of the 
conditions with the advantage of enabling comparison of scores between patients with 
various diseases or against general population. These generic instruments may fail to have 
enough sensitivity to detect differences of particular concern in specific patient groups. 
Therefore, disease-specific instruments have been developed. As young children may have 
difficulties in understanding questions, parents need to add important information on their 
child’s behalf. To overcome children’s difficulties with literacy, Juniper et al. have 
constructed an interview-based instrument to assist these children [74]. Importantly, aspects 
of health experiences may vary between children and parents [75], and such differences may 
be captured with HR-QoL assessment.  
  
Paediatric studies have found association between asthma severity and impairment in HR-
QoL [76, 77]. and suggested that children with poor HR-QoL would benefit from 
psychological evaluation and support [78]. Few studies have evaluated HR-QoL in children 
with asthma longitudinally, but Sundell et al. found improvements over time in adolescents, 
especially in females performing regular physical activity [79]. For children with the most 
severe disease, as patients with problematic severe asthma, the health situation is poorly 
described and needs further analysis.  
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3 AIM 
The overall aim of this doctoral thesis was to evaluate the burden of symptoms and factors 
associated with impaired asthma control in schoolchildren. In particular it set out to:  
 
 Estimate the prevalence of severe asthma and evaluate asthma control in childhood 
asthma based on a prospective Swedish birth cohort (paper I). 
 
 Identify factors in patient history or clinical measures associated with impaired 
asthma control and/or problematic severe asthma as compared with controlled 
asthma (paper I and II).  
 
 Utilize component-resolved allergy diagnostics in children with problematic severe 
asthma and controlled asthma (paper III). 
 
 Evaluate health-related quality of life in children with problematic severe asthma and 
controlled asthma (paper IV).  
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4 MATERIALS AND METHODS 
 
4.1 STUDY DESIGN 
The doctoral thesis is based on two different cohorts; the population-based longitudinal birth 
cohort BAMSE (paper I), and the cross-sectional Swedish multicentre cohort of the Severe 
asthma study (paper II, III and IV).  
 
4.1.1 BAMSE birth cohort  
All children born between February 1994 and November 1996 in a predefined area of 
Stockholm, Sweden were invited to participate in the cohort. The recruitment area was 
selected to represent both urban and suburban environments with a representative variation 
of buildings and socio-economy 
 
A total of 7 221 children were born during the relevant period, of these 477 were unreachable 
due to incorrect address, 1 399 never answered or declined participation and 1 256 children 
were actively excluded. Exclusion was done if the family planned to move within 1 year of 
study enrolment, in case of insufficient language skills in Swedish and if the child was 
seriously ill or an older sister or brother was already included in the study. This resulted in a 
final cohort of 4 089 new born infants. 
 
To analyse if the non-respondents and the actively excluded children differed in relation to 
key exposures such as parental history of allergic disease, and exposure to parental smoke, a 
short questionnaire was sent by mail to 1 418 families with a response rate of 67%. The 
result revealed that parental history of allergic disease was comparable between the included 
and not included children, although parental smoking was more prevalent among not 
included children. 
 
Children in the BAMSE cohort were followed from study enrolment, and after 1, 2, 4, 8 and 
12 years. Almost 84% (n = 3 431) were evaluated at 8 years and 82% (n = 3 346) at 12 years 
[24]. 
 
4.1.2 Severe asthma study 
An invitation to participate in the Severe asthma study was sent to paediatric allergists at 27 
paediatric clinics throughout Sweden. The clinics were represented by members in the 
Swedish severe asthma network. A mobile team consisting of two researchers, Jon 
Konradsen and Björn Nordlund, visited all the 15 participating clinics and conducted data 
collection on site, bringing along and utilizing the same equipment, to ensure a 
standardized data collection of biological samples and measurements, Figure 4. 
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Figure 4. Localisation of paediatric clinics and numbers of children from each respective clinic in the Swedish 
Severe asthma study, n = 96. 
 
 
 
 
Schoolchildren and adolescents 6 to 18 years with problematic severe asthma and controlled 
mild-moderate asthma were recruited. Children with problematic severe asthma used daily 
high-dose of ICS (> 800 µg budesonide or equivalent) and children with controlled asthma 
daily low-to-medium dose of ICS (100 – 400 µg budesonide or equivalent). The patients 
with problematic severe asthma and controlled asthma were age-matched to within 12 
months. Inclusion criteria are listed in Table 2. The study was open for inclusion from 
January 2007 to June 2009. Patients were referred by participating clinics or by review of 
journal charts by Björn Nordlund. The children referred in this manner were invited by mail, 
telephone or verbally in connection with a clinical visit. In addition, acceptable medical 
adherence was required and defined as regular scheduled visits to the doctor and not having 
missed more than three doses of control medication per week (as documented in report 
provided by child/parent). Study exclusion criteria were other lung diseases than asthma, 
such as vocal cord dysfunction, cystic fibrosis and immune deficiency or serious 
neurological diseases or major lung surgery as well as premature birth (< 36 weeks of 
gestation age).  
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Table 2. Inclusion criteria for patients of the Severe asthma study. 
Problematic severe asthma Controlled mild-moderate asthma 
Major criteria: (all required) Major criteria: (all required) 
 Physician-diagnosed asthma  Physician-diagnosed asthma 
 Daily high-dose (≥ 800 μg/day budesonide 
equivalent) ICS treatment in combination with 
LABA and/or LTRA
†
 
 Daily low- to medium-dose (>100 and < 400 
μg/day) ICS treatment‡. Either LABA or 
LTRA use accepted. 
Minor criteria within preceding 12 months 
(minimum one required) 
Minor criteria within preceding 12 months (all 
required) 
 ≥1 emergency hospitalisation  No hospitalisation 
 ≥ 2 emergency out-patient visits  No emergency out-patient visits 
 ≥1 course of oral corticosteroid treatment*  No oral corticosteroid treatment 
 ≥ 12 exacerbations** of asthma / year or 
continuous symptoms during ≥ 3 months 
 ≤ 4 exacerbations of asthma 
 Asthma symptoms limiting daily activity 
(including sport or leisure activities) > 2 times a 
week for ≥ 3 consecutive months. 
 Only occasional activity-related asthma 
symptoms during heavy exercise, otherwise 
without symptoms 
 Nocturnal asthma symptoms > 2 times a week for 
≥ 3 consecutive months. 
 No nocturnal symptoms 
General exclusion criteria for problematic severe asthma and controlled asthma: 
 Other lung diseases×  
 Serious neurological diseases 
 Major lung surgery 
 Premature birth < 36 weeks of gestation age 
ICS: Inhaled corticosteroid; LABA: long-acting β-2 agonist; LTRA: leukotriene receptor antagonist 
†
 High-dose ICS > 6 months preceding year; previous use of LABA or LTRA accepted if discontinued due to no 
benefit or unacceptable side effects. 
‡
 ICS dosage increase < 2 weeks during asthma exacerbations. * Oral-steroid 
bursts were in principle prescribed by a physician. ** Exacerbations of asthma were defined as periods with 
significantly increased asthma symptoms and (self-administered) increase in medication.
 × 
Other lung diseases are e.g. 
vocal cord dysfunction, cystic fibrosis and immune deficiency.    
 
 
 
 
 
   13 
4.2 STUDY POPULATION 
The study population of this thesis consisted of children from two cohorts:  
 Children of the BAMSE cohort who were prospectively evaluated at age 0 to 12 
years with complete data on definition of asthma disease (definition presented in 
4.5) at age 8 and 12, n = 3 015. Children in the BAMSE study (n = 3 015) were 
representative for the original BAMSE cohort at enrolment (n = 4 089) with regard 
to sex, parental history of allergic disease, socio-economy and tobacco exposure. 
Mean ages at 8- and 12-year follow-ups were 8.2 years (±0.5 years) and 12.9 years 
(±0.8 years), respectively. 
 
 Children of the Severe asthma study with problematic severe asthma (n = 56) and 
controlled asthma (n = 39). Information about recruitment and exclusion of patients 
is presented in Figure 5. At the time for arrangement of paper II and IV, data were 
collected from 54 patients with problematic severe asthma. Children with 
problematic severe asthma and controlled asthma were similar with regard to age 
(mean 13.2 vs. 13.8 years, p = 0.34), proportion of girls (41% vs. 41%, p = 0.99), 
Caucasian ethnicity (82% vs. 92%, p = 0.16) and BMI (mean 63 vs. 55 percentile,   
p = 0.17). 
 
 
 
 
 
 
Figure 5. Flow chart over included and excluded patients in the Severe asthma study. 
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4.3 QUESTIONNAIRES 
 
4.3.1 Parental health questionnaires 
In the BAMSE study, data were obtained by parental questionnaire at the time for enrolment 
(mean age 2 months) to collect information on each child’s history of environmental 
exposures, parental history of allergic disease and life style factors. Information about 
asthma symptoms, asthma medication, comorbidities and life style factors were obtained by 
parental questionnaires when children were aged 8 and 12. Body mass index (BMI) kg/m
2 
was calculated and cut-off for overweight BMI was set to the 85th percentile of BMI based 
on children in the BAMSE study, taking sex and age into account [80]. 
 
In the Severe asthma study, patients and their parents were interviewed with use of a 
standardized health questionnaire to obtain information about the children’s history of 
environmental exposures, family history of allergic disease, lifestyle, asthma symptoms, 
asthma medication, comorbidity and adherence to prescribed medication. In addition, the 
child’s inhalation technique was observed in relation to intake of beta-2 agonist prior to and 
after lung function testing. 
 
4.3.2 Asthma control test 
Validated self-reported asthma control tests were employed for assessment of children’s 
asthma control in the Severe asthma study, the Childhood Asthma Control test® (C-ACT) in 
the children up to 11 years of age [38], and the Asthma Control Test® (ACT) for children 12 
years or older [81]. The scores grade from 0-25 for ACT and 0-27 for C-ACT. Independent 
of the test used, a score ranging between 0-19 is considered to reflect uncontrolled asthma, 
whereas controlled asthma is defined by a score of 20 or above.  
 
4.3.3 Health-related quality of life  
HR-QoL was evaluated by interviewing patients in the Severe asthma study. The validated 
Swedish version of the Juniper Paediatric Asthma Quality of Life Questionnaire® 
(PAQLQ(S)) was applied [82]. This questionnaire has been validated for children aged 7-17, 
but it was decided to use it for the two 18-year-old subjects as well. The PAQLQ(S) consists 
of 23 questions divided into three domains termed symptoms, activity limitation, and 
emotional function. The scores range from 1-7 where 1 represents the greatest impairment 
possible and 7 represents the least.  
 
4.4 CLINICAL MEASURES 
 
4.4.1 Conventional allergy diagnostics 
In the BAMSE study, blood sampling was included in the clinical examination of 2 226 
children (74%) at the 8-year follow-up, and in all subjects of the Severe asthma study (n = 
95). Serum was analysed for specific immunoglobulin E (IgE). Tests provided by Phadia 
AB, Uppsala, Sweden, were Phadiatop
® 
containing
 
inhalant allergens of birch, grass, cat, 
dog, horse, mould, house dust mite and mugwort and Fx5
®
 including food allergens of cow’s 
milk, egg white, peanut, soy, cod and wheat [83, 84]. An IgE level of ≥ 0.35 kUA/l 
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designated patients with sensitization. In the Severe asthma study, total IgE (kU/l) was also 
analysed. 
 
In the Severe asthma study, a positive SPT response was considered when the wheal 
diameter was > 3 mm. The tested allergens included inhalant allergens of birch, timothy, 
mugwort, dermatophagoides pteronyssinus, dog, cat, rabbit, cladosporium, alternaria, and 
food allergens of egg, milk, cod, rye, wheat, almond, hazelnut and peanut (Soluprick® SQ, 
obtained from ALK Abelló, Hörsholm, Denmark).  
 
4.4.2 Component-resolved allergy diagnostics 
Serum samples (n = 95) in the Severe asthma study were analysed using an experimental 
research ISAC prototype (Phadia AB, Sweden) containing 111 allergen components (all 
components of the ImmunoCAP ISAC 112 chip version except Ara h 6). The chip contained 
allergens derived from 51 sources, and required 30 µl of serum per test. Details of the tested 
perennial, inhalant and food components are listed in Figure 13. Positive sensitization was 
defined by a level of ≥ 0.30 ISAC independent units (ISU).  
 
4.4.3 Inflammation 
Markers of airway inflammation were analysed in the Severe asthma study, fraction of 
exhaled nitric oxide (FeNO) was determined by a chemiluminescence method using NIOX® 
equipment (Aerocrine AB, Solna, Sweden). Settings were in accordance with European 
Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines [85]. Samples 
of venous blood were collected, and numbers of white blood cell count (WBC, 10
9
 x L
-1
), 
neutrophils (10
9
 x L
-1
) and eosinophils (10
9
 x L
-1
) were analysed.  
 
4.4.4 Lung function and bronchial hyperresponsiveness 
In the BAMSE birth cohort, assessment of lung function was performed at the 8-year follow-
up using dynamic spirometry (2200 Pulmonary Function Laboratory; Sensormedics, 
Anaheim, CA, USA) including forced expiratory volume in one second (FEV1%) in 1 841 
children (61%), and peak expiratory flow rate (PEF, Ferraris Medical Limited, London, UK) 
in 2 318 children (77%). The predicted reference values based on the BAMSE population 
were adjusted for sex, height and age [86].  
 
In the Severe asthma study, patients were evaluated with dynamic spirometry (Vitalograph® 
2120 Ennis of Ireland) utilizing ERS/ATS guidelines. ERS/Polgar reference values were 
applied for estimation of predicted FEV1 values, adjusted for sex, height and weight [87]. 
Bronchial hyperresponsiveness (BHR) was evaluated by a challenge with methacholine 
(delivered by the Spira® Elektro 2 Dosimeter; Respiratory Care Center Ltd., Hämeenlinna, 
Finland) [88] in accordance with ATS guidelines [89]. Patients withheld their asthma 
medication prior to both methacholine challenge and baseline lung function testing. The 
decrease in FEV1 as a response to the cumulative inhaled dose of methacholine was 
calculated using the dose-response slope (DRS) [90].  
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4.5 DEFINITIONS AND OUTCOMES  
The study definition of asthma at 8- and 12-year follow-ups in the BAMSE study required 
fulfilment of at least two of the following criteria [22, 91]. 
 Wheeze (at least one episode) in the last 12 months prior to the date of assessment. 
 Intake of asthma medication regularly or occasionally in the last 12 months prior to 
the date of assessment. 
 A doctor’s diagnosis of asthma (ever).  
Parental reported asthma control in the BAMSE cohort was analysed in the last 12 months 
prior to the date of assessment in children fulfilling the asthma criteria at 8 and/or 12 years, 
using symptom features of limitation in daily activity and nocturnal asthma from GINA [12], 
in combination with features of severe wheezing (wheeze > 4 times in the last year) from the 
ISAAC protocol [92] and healthcare utilization due to acute asthma symptoms (emergency 
visit or hospitalization). In addition, lung function less than 80% of predicted in PEF or FEV1 
was included in the 8-year follow-up [12]. A child’s asthma control was classified as 
follows:  
 Impaired when at least one feature was fulfilled. 
 
 Controlled (0 features). 
 
 Partly controlled (1-2 features). 
 
 Uncontrolled (> 3 features).  
 
Severe asthma was defined as presence of asthma (according to the definition above) and 
pharmacy-suspended prescription of daily high-dose inhaled corticosteroids (ICS) of at least 
> 800 microgram budesonide or equivalent steroid (> 500 µg fluticasone) in combination 
with treatment with a long-acting beta-2 agonist (LABA) according to WHO definition [53]. 
Pharmacy-delivered high-dose ICS was identified during a ± 1.5-year period before and after 
the date of each child’s 12-year follow-up, through the Swedish prescribed drug register. The 
register lists all prescription drugs dispensed to Swedish residents since July 2005 and was 
only accessible at the time of 12-year follow-up [93].  
 
Asthma triggers, e.g. cold air and physical activity, were evaluated as history of symptoms of 
whistling, wheeze, shortness of breath and troublesome cough induced by the trigger in 
question. While the time period for the trigger in question was defined in the BAMSE study 
as the past 12 months, no time period was specified in the Severe asthma study.  
 
Continuous anti-inflammatory treatment included > 2 months use of regular treatment with 
ICS at 8- and 12-year follow-ups or > 2 months of treatment with montelucast at 12-year 
follow-up (BAMSE). 
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Rhinitis was defined as symptoms of prolonged sneezing or runny or blocked nose without 
common cold in the last 12 months (BAMSE) [94]. The Severe asthma study defined 
symptoms of rhinitis and/or conjunctivitis.    
 
Airflow limitation was based on less than 80% of predicted in FEV1 (Severe asthma study 
and BAMSE) or PEF (BAMSE). Reference values in each respective cohort are presented in 
section 4.4.4. 
 
Socio-economic background in children included in the Severe asthma study was defined 
based on total parental income and parental education. Annual income in Swedish kronor 
was defined on a four-point scale (< 350 000, 350 000 – 560 000, 560 000 – 750 000 and > 
750 000) and parental education on a five-point scale (< 9 years, = 9 years, = 12 years, < 3 
years of high school or university, > 4 years of high school or university).  
 
4.6 STUDY ETHICS 
All studies included in the thesis were approved by the ethics committee at Karolinska 
Institutet, Stockholm, Sweden. The longitudinal birth cohort BAMSE was approved at 
baseline, 8-year and 12-year follow-ups with the respective reference numbers; 93:189, 02-
420 and 2007/1634-31. Reference numbers with relation to the Swedish Severe asthma study 
were; 2006/1324-31/1, 2007/443-32. Informed consent was obtained from all subjects.  
 
4.7 STATISTICS 
Statistical analyses were performed with STATA statistical software (release 11.1; Stata 
Corp, College Station, TX, USA) or IBM SPSS statistics software versions 16 to 19 
(Chicago, IL, USA). Binary data was presented as frequencies and percentages and 
continuous variables as means with standard deviation (SD). Differences between normally 
distributed continuous data were analysed using the independent t-test, while non-parametric 
data were assessed using the Mann-Whitney U test. Differences in binary variables were 
analysed in percent with 95% confidence interval (95% CI) or with the chi-square test. A p-
value < 0.05 was considered significant. Relationships between linear variables were 
examined using Pearson’s correlation and non-linear using Spearman correlation coefficient.  
 
Determinant factors associated with impaired asthma control at 8 and 12 years or 
problematic severe asthma were analysed with multiple logistic regression (presented as 
odds ratio (OR) with 95% CI) and as univariate analyses adjusted for age, sex and ethnicity. 
Reference populations were children with controlled asthma in each respective cohort. 
Factors in the children’s history were analysed on the basis of previous known association 
with asthma symptoms [86, 95, 96]. Definitions of these factors in the BAMSE study were; 
parental smoking - any of the parents smoked at least one cigarette per day at the day of 
study enrolment, family history of allergic disease - mother and/or father with doctor’s 
diagnosis of asthma and asthma medication and/or doctor’s diagnosis of hay fever in 
combination with furred animal or pollen allergy at the time of study enrolment, and socio-
economy – status for the household at study enrolment, blue collar, white collar (university 
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graduate jobs) or other (e.g. student, housewife/man, person on a disability pension or 
unemployed).  
 
Receiver operating characteristic (ROC) analysis was performed to estimate the area under 
the curve (AUC), and identify optimal thresholds of sensitivity and specificity for 
PAQLQ(S) and the asthma control test to differentiate problematic severe asthma from 
controlled asthma. The ROC analysis was conducted as a non-parametric test.   
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5 RESULTS 
 
5.1 ASTHMA DISEASE IN THE BAMSE COHORT 
In the population-based cohort BAMSE, 11% of the children fulfilled the study definition 
of asthma at 8 and 12 years respectively (n = 323 / n = 329), which corresponded to 15%         
(n = 458) at either 8 or 12 years, and 6% (n = 194) at both 8 and 12 years. The asthma 
incidence between the ages of 4 and 12 was 9.78 per 1000 person-years.  
 
Children with asthma at both 8 and 12 years were more often boys (61% vs. 50%,               
p < 0.001) and had family history of allergic disease (46% vs. 29%, p < 0.001), compared 
with children without asthma. Sensitization to common inhalants or food allergens at 8 
years was also more common in children with asthma (64% vs. 29%, p < 0.001). In 
addition, tobacco exposure at enrolment was more prevalent among children with asthma at 
8 years (24% vs. 19%, p = 0.03), but not at 12 years (22% vs. 20%, p = 0.24). The 
proportion of overweight was comparable between children with and without asthma at age 
8 (21% vs. 21%, p = 0.89), but higher among children with asthma at age 12 (16% vs. 11%, 
p = 0.015). Any type of asthma medication in the last 12 months was taken by 96% of the 
children with asthma at 8 years and by 94% at 12 years (p = 0.12), however, continuous 
ICS was to a larger extent used in children with asthma at 12 years than at 8 years, 31% vs. 
23% (p = 0.04). 
 
5.1.1 Asthma control 
Characteristics of asthma control were analysed in children with asthma at 8 and/or 12 years 
and independently of asthma treatment in the BAMSE study. The frequency of impaired 
asthma control (partly or uncontrolled) was higher at 8 years than at 12 years, 85% vs. 53% 
(p < 0.001). At 8 years, 27% of 323 children with asthma were uncontrolled and 58% were 
partly controlled. The corresponding proportions at age 12 were 7% with uncontrolled 
asthma and 46% with partly controlled (of 329 children with asthma). Activity limitation 
occurred in 66% at 12 years versus 48% at 8 years (p < 0.001) and severe wheezing              
(> 4 times in last year) in 52% versus 38% (p = 0.002). In contrast, nocturnal asthma was 
less frequent at 12 years, 36% versus 82% (p < 0.001), as was healthcare utilization due to 
acute symptoms, 15% versus 34% (p < 0.001), Table 3. Lung function was assessed at age of 
8 years and 13% (n = 25) of the children with asthma had < 80% of predicted in FEV1 or 
PEF, four of these children fulfilled no other criteria of impaired asthma control.  
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Table 3. Frequency of controlled asthma (0 features) and impaired asthma control (> 1 features) at age 8 and 12 
years, measurement of lung function is not included. 
  8 years 12 years 
  Controlled Impaired control Controlled Impaired control 
 n = 52 n = 271 n = 155 n = 174 
  
% (95% CI) % (95% CI) % (95% CI) % (95% CI) 
Prevalence 16 (12.1-20.1) 84 (79.9-87.9) 47 (41.7-52.5) 53 (47.5-58.3) 
Limitation in daily activities  0 48 (42.4-54.3) 0 66 (59.0-73.2) 
Nocturnal asthma * 0 82 (76.9-86.2) 0 36 (28.4-42.8) 
Wheeze > 4 times 
†
  0 38 (31.8-43.4) 0 52 (44.8-59.8) 
Health care utilization ¡ 0 34 (28.6-40.0) 0 15 (9.6-20.3) 
* Sleep disturbance in relation to cough or asthma symptoms. † Last 12 months prior to assessment. ¡ Hospitalization or 
emergency visits due to asthma symptoms. 
 
Among all children with impaired asthma control (n = 358) at age 8 or 12 years, 25% 
reported impaired at both 8 and 12 years, 51% were impaired only at 8 years and 23% only 
at 12 years, Figure 6.  
 
 
 
Figure 6. Proportions of children with impaired asthma control at 8 and 12 years in the BAMSE cohort. 
 
 
5.1.2 Prevalence of severe asthma  
At 12 years, 0.4% (n=13) of 3 015 children from the BAMSE cohort fulfilled the definition 
of severe asthma, corresponding to 4 % among children with asthma.  
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5.2 FACTORS IN CHILDREN’S HISTORY 
In the BAMSE cohort, children’s history and comorbidities were analysed among children 
reported as having impaired asthma at both 8 and 12 years (n = 91) and compared with 
children with controlled asthma at ages 8 or 12 years (n = 48 and n = 155, respectively). 
Compared with controlled asthma at 8 years, family history of allergic disease OR-adj. 3.3 
(95% CI, 1.35-8.19) and rhinitis OR-adj. 2.8 (95% CI, 1.07-7.26) were associated with 
impaired asthma at 8 and 12 years. At 12 years, boys were overrepresented in the group with 
impaired asthma at 8 and 12 years as compared with in controlled asthma OR-adj. 2.0,    
(95% CI, 1.03-4.00). Treatment of continuous ICS did not differ significantly between 
children with impaired asthma at 8 and 12 years and children with controlled asthma, 38% 
vs. 32%   (p = 0.27). Of children with impaired asthma at 8 and 12 years and rhinitis 68% 
were untreated with nasal steroids the last year prior to the 12-year follow-up   
 
In the Severe asthma study, family history demonstrated that family history of parental 
asthma OR-adj. 3.5 (95% CI, 1.18-10.10) and lower parental education (no formal education 
beyond high school) OR-adj. 3.6 (95% CI: 1.07-12.17) were more associated with 
problematic severe asthma as compared with controlled asthma. Univariate analyses, with 
adjustment for sex, ethnicity and age, showed that a smoking family member OR 2.7      
(95% CI, 1.01-7.10) and that patient history of rhino-conjunctivitis OR 3.7 (95% CI, 1.20-
12.00) were also associated with problematic severe asthma, Figure 7.  
 
 
Figure 7. Factors and comorbidities associated with problematic severe asthma (Severe asthma study) and 
impaired asthma at 8 and 12 years (BAMSE cohort) as compared with controlled asthma in the respective 
cohorts. 
 
5.2.1 Severe difficult-to-treat asthma 
Starting with the problematic severe asthma group (the Severe asthma study), patients were 
further differentiated to be severely therapy-resistant or difficult-to-treat. Aggravating factors 
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in the children’s history were identified through the health questionnaire and designated the 
subgroup of children with difficult-to-treat asthma. Identified factors were untreated 
symptoms of rhinoconjunctivitis (n = 4), current exposure to tobacco (n = 12), untreated 
symptoms of GERD (n = 5), presence of pets in the household despite sensitization to such 
pets (n = 3) and sensitization to moulds in combination with reported exposure of mould or 
humid and problematic indoor climate in a child’s home (n = 4). Thirty-three patients (61%) 
remained classified as therapy-resistant after exclusion of difficult-to-treat asthma (n = 21), 
Figure 8. Children with difficult-to-treat asthma revealed lower parental income on a four-
point scale, median 1 vs. 3 (p = 0.002) and a lower proportion parents with education beyond 
high school, 28% vs. 70% (p = 0.004), compared with children with therapy-resistant 
asthma.      
 
 
Figure 8. Number of patients with problematic severe asthma that were differentiated as having difficult-to-treat 
or therapy-resistant.   
 
5.2.2 Asthma triggers 
Reported asthma triggers in the BAMSE cohort were limited to the past 12 months at the 12-
year follow-up, as opposed to the Severe asthma study where no such time limit was defined. 
The most common triggers reported as inducing asthma symptoms among children with both 
impaired asthma at 8 and 12 years and problematic severe asthma were physical activity 
(84% and 86%, respectively) and viral infections (88% and 93%). In comparison, viral 
infections occurred more often in both impaired asthma at 8 and 12 years and problematic 
severe asthma compared with in controlled asthma in each respective cohort, Table 4. In 
addition, triggers from pollen allergens, cold air and tobacco smoke were also more 
pronounced among impaired asthma at 8 and 12 years and problematic severe asthma, 
whereas furred animal exposure and food allergens were equally distributed between the 
groups.   
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Table 4. Asthma triggers in reported impaired asthma at both 8- and 12-year follow-ups and in problematic 
severe asthma compared with controlled asthma in the respective cohorts. 
 BAMSE Severe asthma study 
  Impaired at 8 
and 12 yr. 
Controlled p - value Problematic 
severe 
Controlled p - value 
  n = 91 n = 155  n = 56 n = 39  
Asthma triggers † n (%) n (%)  n (%) n (%)  
Physical activity 76 (84%) 75 (48%) < 0.001 48 (86%) 33 (85%) 0.89 
Viral infections 78 (88%) 41 (27%) < 0.001 52 (93%) 30 (77%) 0.026 
Cold air 46 (51%) 28 (18%) < 0.001 34 (61%) 10 (26%) 0.001 
Pollen 
¶
 45 (49%) 39 (25%) < 0.001 39 (74%) 19 (49%) 0.020 
Furred animal × 28 (31%) 38 (25%) 0.29 34 (64%) 24 (63%) 0.92 
Tobacco smoke 13 (14%) 6 (4%) 0.003 28 (53%) 11 (29%) 0.023 
Food 5 (3%) 4 (3%) 0.24 19 (34%) 9 (23%) 0.25 
† Asthma triggers were evaluated in the BAMSE cohort as history of symptoms of whistling, wheeze, shortness 
of breath and troublesome cough induced by the trigger in question in the last 12 months. In the Severe asthma 
study no time limit was defined. 
¶ 
Grass and birch allergens. × Cat, dog and horse allergens. 
 
 
5.3 LUNG FUNCTION AND BRONCHIAL HYPERRESPONSIVENESS 
The lung function of children in the BAMSE study was measured at 8 years. Airflow 
limitation (< 80% of predicted in PEF or FEV1) was more common in children with asthma 
compared with children without asthma at 8 years, 8% vs. 4% (p = 0.009), and at 12 years, 
10% vs. 4% (p < 0.001). In children with defined asthma at 12 years, a higher proportion of 
wheeze during common cold was presented in children with airflow limitation at 8 years than 
in children with normal lung function at that age, 70% vs. 50% (p = 0.035). In contrast, 
wheeze without common cold at 12 years revealed no such difference with regard to airflow 
limitation at 8 years and normal lung function, 67% vs. 50% (p = 0.07). The proportion of 
children with air flow limitation at 8 years was comparable between children with impaired 
asthma at both 8 and 12 years and controlled asthma at 12 years, 13% vs. 10% (p = 0.49).  
 
Airflow limitation was more common among children in the Severe asthma study than in 
children with asthma at 8 years in the BAMSE study, 38% vs. 8% (p < 0.001). In addition, in 
the Severe asthma study, children with problematic severe asthma more often displayed 
airflow limitation than children with controlled asthma, 48% vs. 23% (p = 0.013), Figure 9.  
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Figure 9. Proportions of airflow limitation (< 80% of predicted FEV1 or PEF at 8 years) in children at age 12 
years with controlled asthma or impaired asthma at both 8 and 12 years in the BAMSE cohort, and in the Severe 
asthma study comparing controlled asthma with problematic severe asthma.  
 
 
Bronchial provocation with methacholine revealed more pronounced BHR in patients with 
problematic severe asthma (n = 34) compared with controlled asthma (n = 39), DRS mean  
51 vs. 17 (p = 0.01). Twenty children with problematic severe asthma were unable to 
undergo the provocation due to low baseline FEV1 < 70%, or difficulties in withdrawing 
their medication, in addition two children were not challenged owing to technical difficulties 
with installation of nebulizer. Five children with problematic severe asthma were negative to 
the methacholine provocation, defined as less than 20% reduction in FEV1.  
 
 
5.4 ALLERGY DIAGNOSTICS  
 
5.4.1 Conventional allergy diagnostics 
In the BAMSE cohort, sensitization to Phadiatop and/or Fx5 was seen in 65% of children 
with controlled asthma and in 71% (p = 0.82) of children with impaired asthma at both 8 and 
12 years. In multivariate analysis, no increased risk of sensitization was seen in children with 
impaired asthma at both 8 and 12 years OR-adj. 0.7 (95% CI, 0.28-1.98) compared with 
controlled asthma. The proportion of children with sensitization was higher in the Severe 
asthma study compared with children with asthma at 8 years in the BAMSE cohort 82% vs. 
64% (p = 0.027) but not at 12 years (based on sensitization at 8 years) 82% vs. 70%             
(p =0.82). In the Severe asthma study alone, sensitization was equal in positive response to 
SPT, Phadiatop and Fx5 between problematic severe asthma and controlled asthma 82% and 
82% (p = 0.94), as well as to three or more allergens (data not shown).  
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5.4.2 Component-resolved allergy diagnostics 
Taking into account both groups of children with problematic severe asthma and controlled 
asthma in the Severe asthma study, IgE-sensitization with multiplex component-resolved 
diagnostics (CRD) was detected in 80% of 95 children. Fifty-one percent were sensitized to 
pollen, food and perennial aeroallergens, with equal distribution between problematic severe 
asthma and controlled asthma, Figure 10. The most common allergen sources among 
sensitized individuals were cat - 76% (rFel d 1 and 4), birch - 64 % (nBet v 1) and timothy 
grass - 64% (rPhil p 1, 2, 5, 6 and 11). In the food panel, the predominant sensitization was 
to peanut, 42% (rAra h 1, 2, 3 and 9).  
 
 
 
Figure 10. Sensitization to perennial aeroallergen components (1), pollen allergen components (2) and food 
allergen components (3) among children with problematic severe asthma and controlled asthma.    
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1. Perennial aeroallergen components: Dog (rCan f 1, 2, 3, 5), horse (rEqu c 1, 3), cat (rFel d 1, 2, 4), 
mouse (nMus m 1) house dust mites (rBlo t 5, nDer f 1, rDer f 2, nDer p 1, rDer p 2, 10, rLep d 2, 
rEur m 2), cockroach (rBla g 1, 2, 5, 7), Alternaria (rAlt a 1, 6), Aspergillus (rAsp f 1, 3, 6) and 
Cladosporium (rCla h 8), sum=28.  
 
2. Pollen allergen components: Bermuda grass (nCyn d 1), Timothy (rPhl p 1, 2, 4, 5, 6, 11), Alder 
(rAln g 1), Birch (nBet v 1), Hazel (rCor a 1.0101), Japanese cedar (nCry j 1), Cypress (nCup a 1), 
Olive (nOle e 1, 7, 9), Plane (rPla a 1, 2, 3), Ragweed (nAmb a 1), Mugwort (nArt v 1, 3), Goosefoot 
(rChe a 1), Wall pellitory (rPar j 2), Plantain (rPla l 1), Saltwort (nSal k 1) and cross-reactive markers 
of polcalcin (rBet v 4 and Phl p 7) and profilin (Latex rHev b 8, Birch rBet v 2, Timothy rPhl p 12 
and Annual mercury rMer a 1), sum=31. 
 
3. Food allergen components: Kiwi (nAct d 1, 2, 5, 8), Celery (rApi g 1), Apple (rMal d 1), Peach (rPru 
p 1, 3), Cashew nut (rAna o 2), Brazil nut (rBer e 1), Hazel nut (rCor a 1.0.0401, 8, 9), Walnut (nJug 
r 1, 2, 3), Sesame seed (nSes i 1), Peanut (rAra h 1, 2, 3, 8, 9), Soy (rGly m 4, 5, 6), Buckwheat 
(nFag e 2), Wheat (rTri a 14, a 19, nTri aA_TI), Cow’s milk (nBos d 4, 5, 6, 8, lactoferrin), Cod 
(rGad c 1), Egg (nGal d 1, 2, 3, 5), Shrimp (nPen m 2, 4), and cross-reactive components of 
tropomyosin (Anisakis rAni s 3, Shrimp nPen m 1, sum=43. 
 
 
With regard to multi-sensitization to more than three positive components of animal-derived 
lipocalin (nMus m 1, rEqu c 1, rFel d 4, rCan f 1, 2), kallikrein (rCan f 5) and secretoglobin 
(rFel d 1), this were more common in children with problematic severe asthma than in the 
controlled asthma group 25% vs. 8% (p = 0.03), Figure 11.  
 
 
 
Figure 11. Sensitization to more than three animal-derived lipocalin, kallikrein and secretoglobin 
components in patients with problematic severe asthma (n = 56) and controlled asthma (n = 39). The 
components consisted of rCan f 1, 2, 5 (dog); rEqu c 1(horse); nMus m 1(mouse); rFel d 1, 4(cat). 
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5.4.3 Animal-derived sensitization and bronchial inflammation 
In the Severe asthma study, patients with multi-sensitization to more than 3 single 
lipocalin, kallikrein or secretoglobin components (n = 17) were more likely to have 
increased bronchial inflammation of exhaled nitric oxide (FeNO), higher blood count of 
eosinophils and BHR to methacholine compared with those positive to fewer 
lipocalin/kallikrein/secretoglobin components (n = 78), Table 5. HR-QoL and higher 
total IgE were also associated with this multi-sensitized group. No differences were 
found in furred animal ownership or tobacco exposure (parental smoking in the 
household) between the two groups.  
 
In the problematic severe asthma group alone, multi-sensitization to animal-derived 
components showed more impairments compared with patients sensitized to fewer 
animal components, in FeNO 38 ppb vs. 25 ppb, (p = 0.021), blood eosinophils 0.65 vs. 
0.39, (p = 0.021), BHR 112 vs. 28, (p = 0.002) and in total IgE 1279 vs. 331,                 
(p = 0.006). In contrast, no association with reduced HR-QoL was present, but a 
tendency towards increased numbers of exacerbations treated with oral steroids in the 
past year was shown, mean 3.50 vs. 2.49, (p = 0.051).    
 
 
Table 5. Distribution of covariates by sensitization to more than 3 positive animal-derived 
lipocalin/kallikrein/secretoglobin components in the total cohort of patients with problematic severe asthma         
(n = 56) and controlled asthma (n = 39). 
  Sensitized to > 3 animal-derived 
lipocalin/kallikrein/secretoglobin components 
  Yes 
n = 17 
No 
n = 78 
p - value 
Furred pet owner, no (%) 2 (12%) 12 (15%) 0.70 
Smoke exposure 
¶
 no. (%) 2 (12%) 14 (18%) 0.54 
Serum total IgE (kU/L, mean, ± SD) 1090 ± 953 464 ± 601 0.041 
FeNO (ppb, mean, ± SD) 34 ± 23 24 ± 20 0.022 
Blood count of eosinophils (10
9
 x L
-1
, mean, ± SD) 0.56 ± 0.50 0.33 ± 0.32 0.025 
Lung function (predicted FEV1%, mean, ± SD) 86 ± 16 85 ± 17 0.80 
DRS of methacholine 
(% decrease of FEV1, mean, ± SD)  
(n = 12) 
85 ± 105 
(n = 61) 
22 ± 33 0.004 
Negative methacholine PD-20,
† 
no. (%) 1 (8%) 16 (26%) 0.18 
Baseline FEV1% < 70% 
*
 no, (%) 2 (12%) 13 (17%) 0.62 
PAQLQ(S) - total score ,mean, ± SD) 5.5 ± 0.9 6.0 ± 0.9 0.014 
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5.4.4 Cross-reactivity between lipocalin components 
Specific IgE levels of lipocalin components correlated in sensitized individuals in the Severe 
asthma study; rFel d 4 and rEqu c 1 (r = 0.850, p < 0.001), rFel d 4 and nMus m 1 (r = 0.751,   
p < 0.001) and rEqu c 1 and nMus m 1 (r = 0.683, p < 0.001).  
 
 
5.5 HEALTH-RELATED QUALITY OF LIFE  
HR-QoL was only assessed in children of the Severe asthma study. All subjects (n = 93), 
except one, were able to answer the interview-based PAQLQ(S) questionnaire. The average 
PAQLQ-score (including the three sections covering symptoms, activity limitation and 
emotional function) was significantly lower for children with problematic severe asthma than 
for those with controlled asthma, Table 6. 
 
 
Table 6. Assessments of health-related quality of life and asthma control in problematic severe asthma and 
controlled asthma, n = 93. 
  Problematic severe Controlled P-value 
  mean (SD±) mean (SD±)   
PAQLQ(S) – total  5.4 (± 0.8) 6.7 (± 0.3) < 0.001 
PAQLQ(S) – symptoms 5.1 (± 0.9) 6.5 (± 0.4) < 0.001 
PAQLQ(S) – activity limitation 5.3 (± 0.9) 6.5 (± 0.4) < 0.001 
PAQLQ(S) – emotional function 5.9 (± 0.8) 6.9 (± 0.2) < 0.001 
Asthma control test, ACT 17.0 (± 3.3) 22.9 (± 1.7) < 0.001 
 
 
The HR-QoL experienced by girls with problematic severe asthma was significantly lower 
than for boys with problematic severe asthma (5.1 versus 5.6, p = 0.02). Furthermore, all 
girls with problematic severe asthma reported use of short-acting beta-2 agonist more than 
twice per week compared with 66% of the boys (p = 0.03). No other differences were 
found with regard to factors in child’s history, BMI, lung function, inflammation of FeNO 
or WBC or in numbers of exacerbations (data not shown). For children with controlled 
asthma, no difference in HR-QoL or asthma control test was observed between girls and 
boys (data not shown).  
 
Analysis of how well PAQLQ(S) and the asthma control test (ACT or C-ACT) 
discriminate between patients with problematic severe asthma and controlled asthma was 
performed. Receiver operated characteristics (ROC) analysis estimated area the under the 
curve (AUC) for PAQLQ(S) to 0.96 (p < 0.001) and 0.95 (p < 0.001) for the asthma control 
test, Figure 12a. The AUC for each subdomain of PAQLQ(S) was also analysed; symptoms 
0.93 (p < 0.001), activity limitation 0.92 (p < 0.001) and emotional function 0.90               
(p < 0.001), Figure 12b. Optimal thresholds for PAQLQ(S) to discriminate between 
patients with problematic severe asthma controlled asthma were < 6.2 for PAQLQ (85% 
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sensitivity and 97% specificity) and < 20 for the asthma control test (79% sensitivity and 
94% specificity). Thresholds for PAQLQ(S)’s subdomains were < 6.1 for symptoms (81% 
sensitivity and 82% specificity), < 6.1 for activity limitation (85% sensitivity and 87% 
specificity) and < 6.7 for emotional function (81% sensitivity and 87% specificity).  
 
 
 
Figure 12a and b. The ability of PAQLQ(S) – total score, ACT or C-ACT (A), and subdomains of 
PAQLQ(S) – symptoms, activity limitation and emotional function (B), to differentiate problematic severe 
asthma from controlled asthma analysed using receiver operating characteristic curves. 
 
 
In the Severe asthma study, the results of the asthma control test strongly correlated with the 
HR-QoL (r = 0.8, p < 0.001), Figure 13. The figure displays concordance between 
measurements based on the estimated optimal thresholds to differentiate between the patients 
with problematic severe asthma and controlled asthma, for PAQLQ(S), < 6.2 on the y-axis, 
and for the asthma control test (score below 20 vertical line on x-axis). 
 
A 
B 
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Figure 13. Correlation of PAQLQ(S) and the asthma control test (ACT and C-ACT) scores from 
children with problematic severe asthma and controlled asthma (r = 0.8, p < 0.001, n = 93). The 
horizontal line displays the optimal threshold of < 6.2 to differentiate children with problematic severe 
asthma and controlled mild-moderate asthma, and the vertical line shows the optimal threshold of < 20 
for ACT and C-ACT. 
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6 DISCUSSION 
 
The aim of this thesis was to assess the burden of symptoms and factors associated with 
impaired asthma control in schoolchildren. A high burden of symptoms was found in 
children with asthma in the prospective birth cohort BAMSE, and about one in five children 
with asthma was defined as having impaired asthma control at both 8 and 12 years. Children 
with problematic severe asthma in the Severe asthma study suffered from impaired quality of 
life with essential effects on daily activities and emotional function compared with children 
with controlled asthma. 
  
Children with impaired asthma control at 8 and 12 years and problematic severe asthma were 
further analysed regarding factors associated with children’s history and clinical measures 
compared with children with controlled asthma. Factors associated with impaired asthma 
control were parental history of allergic disease and comorbidity of rhinitis. Among children 
with problematic severe asthma, limited health literacy was another factor found in children 
classified with difficult-to-treat asthma, based on concurrent failure to prevent children from 
having asthma symptoms. Sensitization was a common feature among all children with 
asthma in the study population (both in the BAMSE and Severe asthma study cohorts). In 
children with problematic severe asthma, multi-sensitization to animal derived components 
was more pronounced than in children with controlled asthma. Furthermore, children with 
such multi-sensitization demonstrated evidence of more severe eosinophil inflammation than 
children with sensitization to fewer animal-derived components. 
 
6.1 ASTHMA CONTROL 
The ultimate goal of asthma therapy is to allow patients to achieve control over their 
symptoms. In spite of that, a high burden of symptoms was present among schoolchildren 
with asthma in the BAMSE study. One in five children with asthma was classified with 
impaired asthma (partly or uncontrolled) at both age 8 and 12 years.  
 
There are various ways to classify asthma control in children and according to GINA two 
domains are included [12], the first domain reflects burden of symptoms and reduced lung 
function and the second the risk for exacerbations as well as persistent decline in lung 
function. Classification of the first domain in the BAMSE cohort included parental 
assessment of activity limitations, nocturnal asthma, and severe wheezing four or more times 
in the last year (criterion adopted from the ISAAC protocol [92]), as well as reduced lung 
function (at 8 years only). The second domain assessed hospitalization and emergency visits 
due to acute symptoms in the last year. If possible, it would have been preferable to assess 
other features as well in this domain, e.g. treatment frequency with oral steroids. Another 
difference was that asthma control reflected a period of the last 12 months in contrast to 
GINA’s recommended 4 weeks. Moreover, reduced lung function is an important outcome 
associated with reduced asthma control [11], unfortunately, the assessment was not included 
in the 12-year follow-up. When classifying asthma control among schoolchildren it is an 
obvious risk that some children with absence of symptoms have remittent asthma rather than 
controlled asthma. In the CAMP trial, Covar et al. defined remission of asthma based on 
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absence of any asthma activity (asthma medication or symptoms) in the last year prior to 
follow-up [97]. In comparison with the BAMSE study, the risk for misclassification of 
children with asthma remission should be low, since asthma control was only assessed in 
children with defined asthma, which means presence of asthma activity; both wheeze or 
medication in the last 12 months, or only one asthma activity (wheeze or medication) in 
addition to a doctor’s diagnosis of asthma.  
 
In the BAMSE study, age-related differences in children’s asthma control were observed, 
corresponding to more acute health care utilization and nocturnal asthma at age 8, and more 
activity limitations and wheeze (> 4 times last year) at age 12. Moreover, fewer children 
fulfilled the criteria of controlled asthma at age 8 compared with at age 12. In spite of that, 
the overall asthma control cannot automatically be interpreted as improved at 12 years. 
Reasons for this discrepancy may exist, one is that the GINA criterion may not be perfectly 
suited for defining asthma control in childhood asthma due to the natural course of childhood 
asthma including changes over time in symptoms e.g. in comparison to wheeze during 
common cold and allergic asthma. Another is longitudinal changes in parental perceived 
asthma control compared with children’s, mainly underestimation of children’s asthma 
symptoms (39,80). Kuehni et al. also found that parental acceptance of poor asthma control 
was higher than that outlined in guidelines [40]. Taken together, these findings emphasize 
why asthma control should be evaluated with reliable and validated instruments to avoid 
unforeseen changes in health outcomes. Asking children directly, using validated HR-QoL or 
asthma control tests, puts more focus on the child’s own perceived disease burden compared 
with GINA guidelines [98, 99], and should as often as possible be incorporated in paediatric 
healthcare, certainly with older schoolchildren, Figure 14. 
 
 
 
Figure 14. Factors with influence on the outcomes of asthma control in children. 
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A high burden of asthma symptoms was present in the BAMSE study. This finding 
emphasizes the importance of well-functioning asthma care. One reason for poor asthma 
control is wrong diagnosis. If a patient’s symptoms do not respond as expected to treatments, 
the first step before increasing the dose of therapy should be to confirm the diagnosis. 
Ideally, asthma is confirmed on evidence of reversible airway obstruction using spirometry 
or through bronchial provocation [100]. Furthermore, an essential component of successful 
asthma care is patient education. Treatment goals should be established in partnership with 
the child and parents. The patient education needs to address the influence of avoidable 
aggravating factors as triggers in home or school environment [101, 102], and effect of 
comorbidities e.g. rhinitis or GERD [103-105]. Patient adherence to therapy is easily 
overestimated [106], and another critical challenge for paediatric health care. Observed 
inhalation techniques in combination with the right inhaler are important considerations in 
paediatric health care. Metered-dose inhalers may be incorrectly used [107], and some 
children do not have sufficient force or depth when inhaling medication through a dry 
powder device, so the medication fails to enter the lungs [108, 109]. There are devices to aid 
children in performing proper inhalation technique such as whistles giving sound at the 
required inhalation rate and devices designed to release a dose only when the required 
inhalation rate is achieved [110].  
 
6.2 SEVERE ASTHMA 
In spite of a growing interest for research in patients with severe asthma, the majority of 
studies have analysed selected materials which can be regarded as a limitation. In this thesis 
the severe asthma prevalence was analysed in a prospective population-based Swedish birth 
cohort, combined with information of dispensed high-dose ICS from records in the Swedish 
prescribed drug register.  
 
The pharmacy information of dispensed ICS was collected at ± 1.5 years before and after the 
children’s 12-year follow-up, this could be considered a limitation for estimating the 
prevalence of severe asthma. While no standards are available for defining the optimal time 
periods of suspended medications in a drug register in connection with follow-up data in a 
birth cohort, the time period of ± 1.5 years was used, based on the maximum time period for 
children not requiring a doctor’s issuance of new medication prescriptions. It is possible that 
children’s asthma treatment may be changed to high-dose ICS without the requirement of 
pharmacy suspension of new medication, certainly if old medications are still provided. 
Severe asthma is a heterogenic disease and various underlying factors may exist with effect 
on the estimated prevalence, including wrong diagnosis, psychosocial factors, socio-
economy, poor adherence, comorbidities, and environmental exposures [50]. Severe asthma 
among schoolchildren seems to be rare. The prevalence of 0.4% corresponded to 4% of all 
children with asthma at 12 years. This rate is comparable with a Norwegian study [111] as 
well as with a British study in which 4.6% of adults with asthma received step 4 or 5 
treatment according to British guidelines [112].  
 
Studies regarding severe asthma in the last decade are difficult to compare due to various 
nomenclatures and definitions. This stresses the importance of using a global definition that 
facilitates assessments and health care of severe childhood asthma. Ideally, the clinical 
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usefulness of a proposed definition should be analysed in regards to real life data, which is 
rarely done. In this thesis, two different definitions of severe asthma were used, one in the 
BAMSE study and one in the Severe asthma study. Both definitions agreed on treatments 
with high-dose ICS, which the majority of proposed nomenclatures agree on [37, 113]. 
Another major criterion to consider is the level of asthma control, the term ‘problematic 
severe asthma’ emphasizes uncontrolled symptoms while in BAMSE no such criteria were 
applied. One of the reasons for that was that the two most recent proposed nomenclatures 
seem to disagree on the level of achieved asthma control in severe asthma [53, 113]. 
According to the WHO definition, it is acceptable that treatment-resistant severe asthma is 
subdivided into uncontrolled or controlled asthma, since controlled asthma would refer to 
patients whose asthma can only be controlled with the highest level of ICS. In the BAMSE 
study, the broader definition regardless of children’s asthma control was used when 
estimating numbers of children with severe asthma. 
 
6.3 FACTORS IN CHILDREN’S HISTORY  
Although several risk factors are known for development of asthma morbidity, the current 
understanding of factors and characteristics associated with impaired asthma control is 
limited. Main factors associated both with children designated as having impaired asthma at 
8 and 12 years in the BAMSE study and with children with problematic severe asthma in the 
Severe asthma study were family history of allergic disease, comorbidity of rhinitis, and 
triggers of virus, cold air, pollens and tobacco smoke. In patients with problematic severe 
asthma, additional associated factors was lower socio-economy.  
  
6.3.1 Socio-economy and health literacy 
In this thesis, children with problematic severe asthma were more often associated with 
parents not having education beyond high school, as compared with children with controlled 
asthma. In addition, among patients with problematic severe asthma, lower parental 
education and income were more pronounced among children with difficult-to-treat-asthma 
compared with patients with therapy-resistant-asthma. The large proportion of children with 
difficult-to-treat-asthma (39%) was defined upon characteristics in children’s history of 
environmental exposures to tobacco smoke, keeping furred animal at home despite 
sensitization and problematic indoor climate with visible mould or perceived odour of mould 
in spite of sensitization to mould. Untreated comorbidities of GERD and rhinitis were other 
characteristics in children with difficult-to-treat asthma. All these factors were assessed only 
on the basis of patient and parental reports and without visiting the home environment. 
Home visits would probably improve the assessment and result in a larger proportion of 
patients with difficult-to-treat-asthma. In support, Bracken et al. analysed modifiable factors 
in patients with problematic severe asthma by visiting their homes, in 79% of children 
aggravating factors were found that contributed to more severe disease such as 
environmental exposures, psychosocial factors and poor adherence [114]. Traditional patient 
education in clinical practice may not overcome family barriers to follow asthma 
management due to psychological distress. A randomised home-based family intervention 
evaluated the efficacy of targeting asthma management and stressors in low-income children 
with asthma [115]. Outcomes of emergency visits and hospitalizations were improved after 
one year intervention. A similar and promising home-based study with improved asthma 
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control in children with atopic asthma was made by Morgan et al., conducting intervention 
with reduction of environmental exposures and family education [116]. Taken together, an 
individual approach with home visits addressing medical and psychosocial needs is probably 
beneficial for patients with problematic severe asthma. 
 
Failure to understand or follow health information may result in poor adherence, untreated 
and unrecognised comorbidities, not avoiding trigger factors and poor recognition of signs of 
asthma worsening. These aspects are included in the definition of limited health literacy [18]. 
Although there are major gaps in the current knowledge of what brings low health literacy, 
there is an association to general literacy skills [117]. Low health literacy is more common in 
certain groups in the society, such as members of ethnic minorities, immigrants, the poor and 
those with limited education [117]. Aspects of parental health literacy need to be approached 
in children with problematic severe asthma, especially in those defined as “difficult-to-treat”. 
In a large Swedish study, children in families with social adversity were seen to have an 
increased risk for exacerbations and for hospital admissions because of asthma [118]. It is 
also relevant to consider that poor health literacy has larger health effects on children with 
more severe disease than on children with e.g. mild asthma. Importantly, limited health 
literacy emphasizes challenges in targeting both patients and parents with tailored education 
[32], and with information to health care professionals to optimize their communication 
skills. Health education has proven to be effective on disease management in patients with 
low health literacy [119].  
 
6.3.2 Family history of allergic disease 
Family history of allergic disease was a distinguishing factor in both children with impaired 
asthma at 8 and 12 years in the BAMSE study and in problematic severe asthma in the 
Severe asthma study. The findings elucidated the children’s inherited relation to increased 
asthma severity. There are few genetic studies performed in children with severe asthma and 
the genetic causes of enhanced asthma severity remain unresolved. Analysis of gene 
expression is complex, with different levels of mechanisms in relations to various triggers 
from the environment. The DNA sequence is a template for transcription of messenger RNA 
which further determines the translation and production of proteins with effect on the 
pathophysiology of asthma. To enable proper analysis of genetic variants, well-characterized 
patients are a requirement. Specific gene expressions of bitter taste transduction (TAS2Rs) 
has been found in patients from the Severe asthma study with severe therapy-resistant 
asthma in addition to controlled asthma and healthy individuals [120]. The bronchodilatory 
bitter taste receptors are suggested as new targets for therapy.  
 
6.3.3 Rhinitis 
Comorbidity of rhinitis was more common in both children with impaired asthma at 8 and 12 
years in the BAMSE study and in those with problematic severe asthma in the Severe asthma 
study. A surprisingly high proportion of children with impaired asthma at 8 and 12 years and 
rhinitis (68%) were untreated with nasal steroids at 12 years. Importantly, asthma and rhinitis 
are represented as the same entity of allergic diseases and need to be evaluated and treated 
simultaneously [24, 121]. Studies have found links between asthma control and severe nasal 
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disease in children [103], even though the majority of studies are focused on adults [122, 
123]. To date, few randomised control studies have proven any effect of nasal treatment on 
asthma control in children. Kersten et al. found that intranasal corticosteroid treatment of 
allergic rhinitis ameliorated EIA symptoms in children with asthma [124]. Pedroletti et al. 
saw no effect of reduced FeNO in children treated with nasal mometason furoate for 
perennial rhinitis, but signs of nasal and systemic eosinophil inflammation were improved 
[125]. Measurements of rhinitis include symptom scores, visual analogue scale scores [126], 
quality of life assessments [127, 128], and should be incorporated in a patient’s asthma care.  
 
6.3.4 Triggers  
Viruses and physical activity were the most troublesome triggers reported in all children with 
asthma in both BAMSE study and Severe asthma study. Symptoms during physical activity 
are of major concern as the current recommendations are that all children with asthma should 
be able to engage in regular physical activity. In the BAMSE study, children with impaired 
asthma at both 8 and 12 years more often revealed symptoms during physical activity than 
children with controlled asthma. The important pathogenic role of exercise-induced 
symptoms (EIA) is bronchial inflammation and for optimal control of EIA, anti-
inflammatory treatment is required [129]. A surprisingly low number, 38% of all children 
with impaired asthma at both 8 and 12 years, used ICS continuously (minimum period of 2 
months) in the last year prior to the 12 year follow-up. Implications of these findings need to 
be highlighted in clinical practice. EIA should be managed and diagnosed at an early stage in 
order to avoid recurrent symptoms of uncontrolled asthma or other diagnoses. The diagnosis 
of EIA is best confirmed through a standardized exercise test [130], the test has high 
specificity and also indicates how well the child masters physical activity. Alternative 
methods are other measurements of bronchial hyperresponsiveness, such as bronchial 
challenges [131] and lung function testing with reversibility test. Triggers of cold air and 
physical activity are closely related since both triggers induce symptoms through the 
combined mechanisms of water and heat loss through respiration, which cause 
bronchoconstriction in bronchial smooth muscle [132, 133]. Children with impaired asthma 
at 8 and 12 years and with problematic severe asthma reported more symptoms in relation to 
cold air exposure than children with controlled asthma. This was associated with more severe 
bronchial hyperresponsiveness, which was confirmed through the methacholine provocation 
conducted in patients with problematic severe asthma and controlled asthma. 
 
Viruses were significantly associated with impaired asthma at both 8 and 12 years and 
problematic severe asthma as compared with controlled asthma. Rhinoviruses (RV) are often 
the primary cause of common cold [134], and severe exacerbations of chronic respiratory 
disease [135]. Unlike many other viral infections that sometimes confer lifelong protection, 
the RV can occur throughout the year and may infect the same individual several times each 
year [136]. Recent findings in immune responses towards RV have identified proteins that 
map to antibody responses and explain a misdirection of antibody responses in RV-infected 
humans, these findings are a crucial first step towards development of a vaccine against RV 
[137]. An effective vaccine against RV is an elusive goal and would extensively reduce the 
burden of respiratory symptoms and exacerbations in respiratory health care.  
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Pollen was another trigger causing more symptoms among children with impaired asthma at 
both 8 and 12 years and problematic severe asthma, emphasizing the role of sensitization to 
common aeroallergens in symptomatic asthma. Sensitization is one of the strongest risk 
factors for asthma but per se rarely leads directly to persistent impaired asthma [6, 138]. In 
support, children with impaired asthma at 8 and 12 years and problematic severe asthma 
were comparable in specific IgE to children with controlled asthma in each respective cohort. 
Instead, studies have demonstrated synergism between allergens and viruses in severe 
exacerbations [139, 140], most notably is that viral infections drive the disease development. 
For high risk individuals, such as children with problematic severe asthma, new prophylactic 
antiviral treatments during seasons of RV would open for prevention against severe 
exacerbations, meanwhile early immunotherapy in appropriately selected children is also 
useful for disease prevention [141].  
 
Tobacco smoke was a significantly more common trigger in impaired asthma at both 8 and 
12 years and in problematic severe asthma than in children with controlled asthma. It is well-
known that tobacco smoke reduces the sensitivity to ICS [142], and increases the risk for 
hospital admission and morbidity compared with the risk among non-smokers with asthma 
[143, 144]. As with active smoking, exposure to passive smoke has a number of severe 
effects on asthma control and severity in children [145]. Therefore smoking cessation in 
relation to childhood asthma is absolutely crucial. Children’s health status would benefit if 
parents and children quit smoking.       
 
6.4 LUNG FUNCTION AND BRONCHIAL HYPERRESPONSIVENESS 
Assessment of airflow limitation less than 80% of predicted in FEV1 or PEF was greater in 
the Severe asthma study compared with among children with asthma in the BAMSE study. 
Airflow limitation was most predominant in children with problematic severe asthma. 
Despite that, airflow limitation at 8 years in the BAMSE cohort was associated with more 
wheezing during viral infections in children with asthma at 12 years than in children with 
asthma and normal lung function. This finding indicates that children with airflow limitation 
are prone to more severe effects from viral infections than children with normal lung 
function. Thus, controlled randomised interventions have to prove this hypothesis, as 
children with airflow limitation could to a larger extent benefit from preventive treatments 
and interventions against viral infections than children with normal lung function.  
 
Although children with controlled asthma in the Severe asthma study were included as a 
reference group to children with problematic severe asthma, these children also revealed 
more airflow limitation than children with asthma in the BAMSE study. This indicates that 
all these children, in spite of reported symptom control and continuous treatment with ICS, 
were not sufficiently controlled in their asthma. However, findings of airflow limitation 
among children with problematic severe asthma is comparable with other studies [111, 146, 
147], and raise concerns about long-term health effects. Few studies have evaluated 
persistent airflow limitation longitudinally in patients with severe asthma. In the TENOR 
study, risk factors in adults were older age, male sex, black ethnicity, current or past smoking 
and longer asthma duration [148], whereas higher education was a protective factor. The 
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clinical implication of these results for paediatric health care is health education preventing 
children and adolescents from taking up smoking.  
 
It is noteworthy that, although more pronounced BHR was seen in children with problematic 
severe asthma, five children were negative to bronchial provocation with methacholine. This 
raises a question about these children’s asthma diagnosis, and required additional asthma 
diagnostics.  
 
6.5 CONVENTIONAL ALLERGY DIAGNOSTICS 
Sensitization to specific IgE of common inhalant and food allergens remained almost 
comparable between children in the Severe asthma study and children with asthma in the 
BAMSE study. No differences were found in the respective cohorts in relation to the 
children’s level of asthma control or severity. Sensitization as measured with conventional 
allergy diagnostics is a common comorbidity in children with asthma, the risk for impaired 
asthma control seems to be more dependent on the background of sensitization in 
combination with other triggers than sensitization alone. 
  
6.6 UTILIZING COMPONENT-RESOLVED ALLERGY DIAGNOSTICS  
In the Severe asthma study, sensitization was analysed utilizing component-resolved allergy 
diagnostics (CRD). IgE-profiles with more than three single animal-derived lipocalin, 
kallikrein and secretoglobin components differentiated children with problematic severe 
asthma from children with controlled asthma. Furthermore, markers of BHR and 
eosinophilic bronchial and systemic inflammation were more pronounced among children 
with multi-sensitization to lipocalin, kallikrein and secretoglobin components. In multi-
sensitized children with problematic severe asthma, a tendency was revealed toward an 
increased number of treated exacerbations with oral corticosteroids in the last year.  
 
Taken together, CRD added new information about children’s sensitization and asthma 
severity compared with conventional diagnostics. CRD also identified a pattern of cross-
reactivity within the lipocalin family. This improves the knowledge of how sensitization to 
different species of furred animals are related. It also enables health care professionals to be 
more specific about which species of furred animals should be avoided in order to prevent or 
ameliorate patient symptoms. Exposure and sensitization to domestic animals are common 
among children [149, 150]. The effects of indoor exposures on allergy development have 
been debated, in a recent meta-analysis of pet ownership in infancy the risk in children was 
neither increased nor reduced for development of allergic symptoms later during school-age 
[151]. In sensitized individuals allergic symptoms to domestic furred animals are a health 
problem difficult to avoid, especially for children [152]. Indirect allergen exposures in a 
school environment with many cat owners have been associated with increased burden of 
asthmatic symptoms [102].  
 
The effect of sensitization in preschool children has been demonstrated through the use of 
quantitative analysis of numbers of positive sensitizers and IgE-levels, correlating with 
increased probability of asthma symptoms and reduced lung function [153, 154]. Subsequent 
studies have followed this field and investigated the association between exposures and 
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asthma severity. Matsui et al. found that allergen levels in the environment (although not cat 
allergen levels) correlated with IgE-levels and that high IgE-levels were associated with 
more severe asthma (5). Multi-sensitization has demonstrated evidence of a role in relation to 
persistent [97] and severe asthma [147]. Allergen exposure drives increased inflammation in 
mucosa and reduces barrier function, which promotes development of symptoms and 
sensitization. In vitro, basophil CD-sensitivity response measured additive dose-response of 
CD63 from a combined challenge with cat, timothy and mite allergens compared with a 
single or double challenge with the same allergens in the same patients [155], this 
experiment showed more severe immune responses in multi-sensitized individuals.   
 
Today’s use of crude allergenic extracts in allergen-specific immunotherapy (SIT) will in 
future be tailored with recombinant allergen-based vaccines [156]. New vaccines based on 
recombinant proteins with less allergenic activity are being developed, with the aim to make 
them free from side effects and with prophylactic action against allergic symptoms. 
Meanwhile, new therapies are being developed, treatment with temperature-controlled 
laminar airflow (TLA) shows promising effects [157]. A TLA device is placed beside the 
patient’s bed and reduces inhalant exposure during sleep, and randomised, placebo-
controlled intervention improved the patients’ HR-QoL and reduced bronchial inflammation 
and cat-specific IgE [158]. Additionally, for patients with severe allergic asthma treatment 
with omalizumab, a humanized monoclonal anti-IgE antibody, is recommended to reduce 
exacerbations and symptoms [52].  
 
6.7 HEALTH-RELATED QUALITY OF LIFE 
In the present thesis, children with problematic severe asthma were found to have more 
impaired HR-QoL compared with children with controlled asthma. This finding indicates 
that children with problematic severe asthma have essential health effects on daily activities 
and emotional function. Children with severe asthma to a larger extent experience feelings of 
exclusion and dissatisfaction compared with children with controlled asthma. Such feelings 
are easily overlooked in clinical practice, and therefore it is recommended to evaluate 
requirements for psychological support to patients with severe asthma. In addition, 
psychological educational programs with family therapy have shown positive effects in 
terms of symptom-related outcomes [159], which potentially could improve the prognosis of 
severe asthma.  
 
Children’s HR-QoL assessed with PAQLQ(S) correlated strongly with the asthma control 
test, indicating a strong impact of asthma control on children’s HR-QoL. Both measurements 
showed high probability to differentiate between problematic severe asthma and controlled 
asthma. Measurements of HR-QoL are not always included in guidelines for management of 
severe childhood asthma [72], which diminished evaluation and support of children’s 
psychological health status. In the present study, to facilitate use of PAQLQ(S) and ACT in 
clinical practice, reliable cut-offs were analysed through ROC curve analysis. Both the 
PAQLQ(S) and the asthma control test can assist the management of problematic severe 
asthma towards closer achievement of controlled asthma. In comparison, the conduct of 
PAQLQ(S) is more time-consuming for patients and health care professionals than the 
asthma control test, but the PAQLQ(S) adds more information about both asthma control and 
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psychological wellbeing. Furthermore, in paediatric health care, HR-QoL assessments have 
proven to be beneficial to the communication between patient and clinician [160], as well as 
between child and caregiver [75].    
 
6.7.1 Sex differences 
It is well known that boys before puberty to a higher degree than girls are identified to have 
asthma [161], but after puberty, a shift is seen with higher prevalence of female asthma 
[162], which is due to both increased incidence and decreased remission of asthma in 
females compared with males [163]. In line with these observations presence of asthma was 
more common in boys up to the age of 12 years in the BAMSE study. In addition, among 
children with reported impaired asthma at both 8 and 12 years compared with controlled 
asthma, boys occurred more frequently, emphasizing that asthma control, as defined in the 
BAMSE study, was more impaired in boys compared with girls up to the age of 12 years.  
 
The assessment of HR-QoL in the Severe asthma study showed that girls with problematic 
severe asthma had significantly lower HR-QoL than boys. Moreover, all of the girls but only 
66% of the boys inhaled rescue of short-acting β-2 agonist more than twice a week. No other 
data indicated that underlying severity of asthma was worse among these girls with 
problematic severe asthma. In support, sex differences in HR-QoL have also been observed 
in children with other diseases than asthma [164]. The interpretation of these findings is that 
girls’ more impaired HR-QoL probably reflects differences in girls’ and boys’ perceptions of 
symptoms, which is supported by Killian et al., demonstrating more intense dyspnoea in 
females during bronchoconstriction induced by methacholine provocation compared with in 
males [165]. According to Osborne et al., sex differences could reflect different 
psychological responses to asthma, rather than actual differences in the disease itself [166]. It 
is possible that non-adherence to therapy to a larger extent is shown in patients suffering 
poor perception of symptoms. A population-based birth cohort from New Zealand analysed 
risk factors for hospital admission for asthma up to the age of 26 years and one determinant 
was male sex [167]. The group of subjects with hospital admission suffered impaired lung 
function and increased bronchial responsiveness to methacholine. These impairments were 
associated with undertreatment since only 10% and 21% reported use of ICS and short-
acting beta-2 agonist, respectively. There is limited knowledge about how to manage patients 
with poor symptom perception, bronchial provocation may somewhat improve patients’ 
perception and diagnosis of underlying BHR [168], but the long-term effect is unknown. To 
improve perception of asthma symptoms patients could use action plans which include self-
monitoring of symptoms or PEF for treatment of exacerbations [169]. Intervention with 
parental support and education have shown promising effects on improved perception in 
parents [170]. 
 
6.8 STRENGTHS AND WEAKNESSES 
The present thesis was based on children in two different cohorts: the BAMSE birth cohort 
with a longitudinal study design and the multi-centre cross-sectional Severe asthma study 
with a selected material of patients. The population-based design of the BAMSE study 
allows us to generalize findings and compare children’s asthma characteristics with healthy 
individuals. The BAMSE study has a prospective design, with relatively small losses of 
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subjects since study start, the study also includes well defined exposures permitting 
comprehensive analyses of disease and symptoms. A general limitation concerning large 
population-based cohorts is that they are less suitable for studying rare diseases. For this 
thesis, the study population of BAMSE was too small for extended analyses of children with 
severe asthma. The 12-year follow-up included only questionnaire data, which without other 
objective measures of asthma is a clear limitation. Although children with impaired asthma 
at both 8 and 12 years and children with problematic severe asthma were compared with 
controlled asthma in each respective cohort, the reference population with controlled asthma 
was differently constituted in asthma severity between BAMSE and the Severe asthma study 
as regards ICS treatment. In the Severe asthma study, all children with controlled asthma 
were selected on the basis of continuous ICS, whereas 32% of children in the BAMSE 
cohort revealed continuous ICS treatment.  
 
The multi-centre design of the Severe asthma study was required to ensure as many children 
as possible, 15 paediatric clinics throughout Sweden referred 56 patients with severe asthma. 
Strength with the Severe asthma study was the comprehensive clinical protocol, making a 
detailed characterization of problematic severe childhood asthma possible. Furthermore, 
inclusion and examinations of all subjects were performed by two of the researchers, Jon 
Konradsen and me, Björn Nordlund, using the same equipment and standardised 
assessments, and thereby providing a uniformity that is uncommon for multicentre studies. 
Limitations with the Severe asthma study are a small population of children to study and the 
cross-sectional design which hampers analysis of finding robustness. Despite intense efforts, 
we were not able to include a group of children with controlled asthma equally large as the 
group with problematic severe asthma. The reasons for that were stringent criteria for 
children with controlled asthma group, such as age-matching to patients with problematic 
severe asthma. Children with controlled asthma may also have experienced less motivation 
to participate since the advantages involved were less pronounced. Another factor is that all 
inclusion was performed in paediatric specialist clinics for allergy or pulmonology, the 
number of children with controlled asthma is limited in these clinics, especially when the 
asthma is under control and no other comorbidities exist the patient is likely to be transferred 
to primary health care.  
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7 CONCLUSIONS 
 
The burden of symptoms was high among schoolchildren with asthma, about one in five 
children reported impaired asthma control at both age 8 and 12 years. The most common 
factors of impaired asthma control were family history of allergic disease and comorbidity of 
rhinitis.  
 
 Age-related differences in parental reports of children’s asthma control were seen, 
underlining the importance of using validated measures of asthma control in 
paediatric health care, with a focus on the patient’s own perception. 
 
 The prevalence of severe asthma is 0.4% in a Swedish urban population and 4% 
among children with asthma.  
 
 Children with problematic severe asthma were to a high degree classified as difficult-
to-treat, based upon characteristics in these children’s history as regards 
environmental exposures and untreated comorbidities. Family history of children 
with difficult-to-treat asthma was associated with lower socio-economy. Further 
studies are needed to improve the knowledge on how to manage these children in 
paediatric health care.  
 
 In comparison to conventional allergy diagnostics, component-resolved allergy 
diagnostics revealed that children with problematic severe asthma were associated 
with multi-sensitization to animal-derived components of secretoglobin, lipocalin and 
kallikrein. These children showed evidence of more severe eosinophilic bronchial 
inflammation than children sensitized to fewer animal-derived components. 
Component-resolved allergy diagnostics may prove useful in asthma severity 
evaluation.   
 
 Children with problematic severe asthma suffer from more impaired health-related 
quality of life than patients with controlled asthma, including essential effects on 
daily activities and emotional well-being. A difference was observed in reports from 
children with problematic severe asthma, with girls perceiving a more impaired 
health-related quality of life than boys. Children’s quality of life needs to be included 
in asthma severity assessment.  
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8 FUTURE PERSPECTIVES 
 
Findings of this thesis show that paediatric health care has challenges in reducing the burden 
of symptoms in schoolchildren with asthma and improving the quality of life in children with 
severe asthma. Additional research is needed to involve health care professionals in 
managing underlying and associated factors in children with impaired asthma control and 
poor treatment response. An increased involvement would facilitate design and 
implementation of new asthma care programs in paediatric health care.  
 
In order to follow up the high proportion of children suffering from impaired asthma control 
at 8 and 12 years in the BAMSE cohort, a proximal evaluation has been done in children at 
16 years. Clinical examination with measurements of lung function, bronchial inflammation 
and blood analysis were applied, together with questionnaires containing information about 
children’s history of allergic diseases. A major advantage of the 16-year follow-up is a larger 
extent of objective measurements of asthma severity than at the 12 years’ assessment. 
Extensive data collection provides new study opportunities relating to factors associated with 
asthma control. Particularly interesting areas to study are the role of sensitization to animal-
derived allergen components in adolescents with asthma. Another opportunity is to analyse 
factors associated with airflow limitation and inflammation among adolescents with asthma. 
Findings in the BAMSE study demonstrated evidence of a great impact of viral infections on 
asthma control. New diagnostics are being developed for analysing effects of rhinovirus on 
asthma control and sensitization.  
 
Proposals for randomised controlled trials exist based on the findings of the present thesis. In 
particular, one identified topic for further studies is the effect of nurse-led home visits to 
explore aggravating factors that inhibit improvements in children’s asthma control. The 
intervention should include family support with education and actions against identified 
barriers in children’s homes, such as environmental exposures, poor adherence or 
psychosocial factors that hinder families from obtaining and following health information.  
 
Another clinical challenge is comorbidity of rhinitis, which was a common feature among 
children with impaired asthma control at 8 and 12 years and with problematic severe asthma. 
The association of rhinitis to asthma control seems to be more pronounced in patients that 
have never received nasal corticosteroids [103]. A randomised clinical trial could further 
clarify the effectiveness of nasal steroids on asthma control in children.  
 
Primary prevention with allergen avoidance is difficult to perform in real life, but is possible 
through nocturnal temperature laminar airflow (TLA) treatment [158]. TLA treatment is 
used during the patient’s sleep and has no side effects on patient health. A future perspective 
is to analyse the effectiveness of treatment with TLA on development of sensitization and 
exposure. Preschool children with severe wheezing and family history of allergic diseases 
are a group of particular interest. It is worth noting that primary prevention studies 
investigating the effect of allergen avoidance on the development of allergic diseases are 
long-term and therefore costly.  
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Respiratory diseases other than asthma need further clinical evaluation in paediatric health 
care. The purpose is to improve the overall understanding of the health effects of lung 
diseases in children. Long-term effects in children born with e.g. bronchopulmonary 
dysplasia (BPD) are largely unknown and poorly defined in schoolchildren. Our research 
team has recently collected data from children with diagnosed BPD and asthma to conduct 
an analysis with two comparable age- and gender-matched groups. Although respiratory 
diseases of BPD and asthma occur differently, the perception and psychological responses on 
health-related quality of life may be similar in these diseases. Other aspects of BPD and 
asthma are inflammatory markers that could be analysed in relation to children’s disease 
burden and responses to treatment. To date, long-term requirements related to health care for 
children with BPD are unknown and need to be explored.  
 
Finally, longitudinal data in children with asthma is lacking. Health registers with data from 
children with asthma could provide a foundation for generating greater understanding about 
health needs. A national asthma register is planned in Sweden. Potentially, the register could 
provide important information to all actors in the health system, from health care providers to 
health care professionals and patients. Patients should be able to use the register for their 
own purposes, to better control their asthma. Health care providers could benefit by taking 
part of information for planning and distributing resources to the health care system. The 
benefit for health professionals would be to gain more specific information about patients, 
which could be applied in the health care system, and researchers could obtain data from the 
health register in a more efficient way than through managing large cohort studies. 
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9 SAMMANFATTNING PÅ SVENSKA 
 
Astma är en global sjukdom som förekommer hos cirka tio procent av alla barn i Sverige. 
Astma är en inflammatorisk luftvägssjukdom som kännetecknas av en överkänslighet och 
en sammandragning av luftrören. Detta orsakar hosta, andningsbesvär och täthetskänsla i 
bröstet. Några av de vanligaste utlösande orsakerna till astmasymtom hos barn är 
virusinfektioner, ansträngning och allergier.  
 
Astma bör klassificeras för att tydliggöra och underlätta bedömningen av barns och 
ungdomars behov av vård och behandling. Astmakontroll kan definieras som den grad av 
symtom som påvisas hos patienten, tillsammans med den samlade riskbedömningen för att 
patienten ska drabbas av symtom eller försämrad lungfunktion. För att utvärdera 
astmakontroll på kliniken finns olika metoder. En är att fråga förälder och barn, en annan 
att använda validerade frågeformulär som patienten själv fyller i. Dessa formulär kan på ett 
standardiserat sätt underlätta utvärderingen av patientens astmakontroll. Målsättningen 
med astmavård är att patienten ska uppnå god kontroll av sin sjukdom utan allvarliga 
medicinska biverkningar eller försämrad livskvalitet. Välfungerande vård med 
patientutbildningen är en förutsättning för att behandlingsmålen ska uppnås. Barn och 
familj behöver kunskap om hur man tar sina läkemedel på rätt sätt, de behöver även 
informeras om vad som utlöser symtom och försämringar, samt hur dessa undviks. En 
lyckad patientutbildning förutsätter en bra kommunikation mellan vårdgivare och patient. 
En annan viktig faktor är patientens och familjens förmåga att ta till sig hälsoinformation 
och följa den. Studier har visat att nedsatt förmåga att följa hälsoinformation resulterar i 
sämre astmakontroll och ett ökat behov av sjukvård.  
 
När det gäller astmans svårighetsgrad kan den definieras efter patientens erforderliga dos 
av läkemedel för att uppnå astmakontroll. Hos de flesta varierar svårighetsgraden över tid, 
en kontinuerlig astmavård underlättar bedömningen av vilken typ av behandling som är 
nödvändig.  
 
Svår astma hos barn kännetecknas av bristande astmakontroll trots hög dosering med 
antiinflammatoriska läkemedel. Barn med svår astma har stort behov av sjukvård och 
sjukdomen riskerar att leda till frånvaro från skola eller förskola. Den orsakar 
inskränkningar och begränsningar i barnets och familjens dagliga liv. Förhållandevis lite 
forskning finns på patientgruppen barn och ungdomar med svår astma, och många aspekter 
av sjukdomen är okända.  
 
Allergier är särskilt vanliga hos barn och ungdomar med astma. Detta ger upphov till ökad 
inflammation i luftrören och ökade besvär vid exponering av allergen som patienten är 
överkänslig mot. I astmavården är det därför viktigt att diagnostisera allergier för att kunna 
ge råd om hur exponering ska kunna undvikas vid påvisad allergi. Effekter av astma på 
barns och ungdomars livskvalitet är viktiga att belysa för att på bästa sätt stödja och 
underlätta barns liv med en kronisk sjukdom. Särskilt lite kunskap finns om hur barn med 
svår astma mår, vilka begränsningar sjukdomen orsakar och vilka psykologiska aspekter 
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som är viktiga för sjukvården att åtgärda.    
 
Målet med den här avhandlingen var att studera förekomsten av symtom och faktorer som 
är associerade med bristande astmakontroll hos skolbarn, med särskild vikt på att:  
• Analysera förekomsten av svår astma hos skolbarn i normalbefolkningen. 
• Identifiera faktorer i barnens sjukdomshistoria som är relaterade till bristande 
astmakontroll och svår astma i jämförelse med lindrig astma. 
• Utnyttja komponentbaserad allergidiagnostik och jämföra allergier mellan barn 
med svår och lindrig astma. 
• Utvärdera livskvalitet hos barn med svår astma i jämförelse med lindrig.   
 
Den här avhandlingen baseras delvis på den populationsbaserade födelsekohorten BAMSE 
där 3 015 barn i åldrarna 8 och 12 år analyserats. Studiepopulationen bestod ursprungligen 
av 4 089 barn som inkluderats från Stockholmsregionen under åren 1994 till 1996. 
Enkätdata är insamlade sedan nyföddhetsperioden med bakgrundsfaktorer som ärftlighet 
för allergisjukdom, exponering för tobaksrök, livsstil mm. Därefter har data samlats in via 
enkäter rörande möjliga astmasymtom, sjukvård och miljöfaktorer. Information om 
ordinerade läkemedel och uthämtade läkemedel finns i det Svenska läkemedelsregistret. I 
registret finns information om alla uttag av läkemedel som gjorts åt barnen i BAMSE-
studien. Detta gör det möjligt att identifiera antalet barn med hög-dos behandling med 
antiinflammatoriska läkemedel som kan klassificeras som svår astma. Astmakontroll 
baserades på föräldrarnas rapportering av symtom hos barnen vid 8 och 12 års ålder.  
 
Avhandlingen innehåller också barn och ungdomar från den nationella studien om svår 
astma. Från 15 kliniker har 56 barn inkluderats med svår astma och jämförts med 39 barn 
med lindrig astma. Information om barnens sjukdomshistoria har precis som i BAMSE-
studien samlats in. I tillägg har barnen rapporterat sin hälsorelaterade livskvalitet med hjälp 
av frågeformulär, tillsammans med mätningar av lungfunktion, inflammationsmätningar i 
luftrören och i blodet. Allergitester har gjorts för att studera förekomst av IgE-antikroppar.  
 
Bland barn med astma i BAMSE-studien var förekomsten av bristande astmakontroll vid 8 
år hela 84 procent, och vid 12 år 53 procent. Tydliga skillnaderna sågs i föräldrarnas 
rapportering med högre andel barn med nedsatt astmakontroll vid 8 år än vid 12 år. Även 
andelen med symtom varierade i stor utsträckning, med mer aktivitetsbegränsningar på 
grund av astma och ökade episoder av väsande andning vid 12 år än vid 8 år. Nattliga 
astmasymtom och akuta sjukvårdsbesök på grund av astma var däremot vanligare vid 8 år. 
Resultaten understryker att även om astmasymtom ser ut att minska vid 12 år kan detta inte 
automatiskt tolkas som en klar förbättring, snarare tydliggörs behovet av att utvärdera 
barnens upplevelse av symtom i stället för föräldrarnas. Det föreligger en klar risk att 
föräldrarna underskattar barnens astmakontroll. I BAMSE-studien var 13 barn identifierade 
med svår astma med hjälp av det Svenska läkemedelsregistret, vilket motsvarar 0,4 procent 
av normalbefolkningen och 4 procent bland alla barn med astma runt 12 års ålder.  
 
Hos 91 skolbarn med bristande astmakontroll vid 8 och 12 års ålder i BAMSE-studien 
samt 56 barn med svår astma från Svår astma-studien utvärderades faktorer i barnens 
sjukdomshistoria, nästäppa och snuva och förälder med allergisk sjukdom var vanligare 
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hos de barnen i jämförelse med lindrig astma. I övrigt var 68 procent av barnen i BAMSE-
studien obehandlade trots symtom med nästäppa och snuva, bland barn med svår astma 
endast 7 procent.  
 
Bland 39 procent av barnen med svår astma fanns faktorer i barnens sjukdomshistoria som 
ökade risken för astmabesvär och gjorde barnen mer svårbehandlade. Dessa faktorer var 
bland annat obehandlade besvär av nästäppa och snuva samt gastrit, exponering av rökning 
från föräldrarna eller ungdomen själv och förekomsten av pälsdjur i hemmet trots att barnet 
påvisats med allergi mot samma djur, samt problem med mögel i bostaden trots påvisad 
allergi mot mögel. Gemensamt hos de här skolbarnen var lägre socioekonomi (föräldrarnas 
utbildningsnivå och årsinkomst) i jämförelse med övriga barn med svår astma. Resultaten 
tolkas som att familjerna har en bristande förmåga att följa hälso-sjukvårdens råd att 
förebygga symtom och därigenom minska effekterna av astmasjukdomen. Ökat fokus på 
patientutbildning och hembesök föreslås kunna stärka de här familjernas förmåga att 
förbättra barnens hälsa.  
 
Majoriteten av barnen med astma i BAMSE- och Svår astma-studien hade en allergisk 
läggning när vi analyserade IgE-antikroppar i deras blod. Inga tydliga skillnader var 
presenterade mellan bristande astmakontroll vid 8 och 12 års ålder, svår astma eller lindrig 
astma med traditionell allergidiagnostik. I traditionell allergidiagnostik finns alla proteiner 
från testade allergen i samma extrakt, till skillnad från komponentupplöst allergidiagnostik 
som baseras på specifika proteiner från varje allergen. Med komponentupplöst diagnostik 
fanns skillnader mellan svår och lindrig astma. Flera olika IgE-antikroppar mot pälsdjur 
från katt, hund, häst och mus var vanligare bland en större del av skolbarnen med svår 
astma, 25 procent respektive 8 procent. Dessutom hade barnen med flera olika antikroppar 
mot pälsdjur i större utsträckning ökade tecken på luftvägsinflammation än de som 
analyserats med färre av dessa IgE-antikroppar. Detta öppnar upp för att minska 
exponering och effekten av pälsdjursallergen hos barn med svår allergisk astma. Nya 
behandlingsmetoder finns att tillgå som luftrenare som bara används på natten när barnet 
sover och injektioner med anti-IgE behandling som minskar effekten av den 
allergiskareaktionen. Besök av hem och skola kan möjliggöra identifiering av källor av 
allergen exponering, viket bör undersökas i framtida studier.  
 
Hos barnen med svår astma var livskvaliteten tydligt försämrad i jämförelse med dem som 
hade lindrig astma. Det betyder att skolbarn med svår astma i ökat omfång upplever 
begränsningar i dagliga aktiviteter och upplever fler känslomässiga problem på grund av 
astma än hos barn med lindrig astma. I vården av barn med svår astma bör också barnens 
emotionella välbefinnande observeras och stödjas. Kommande studier bör undersöka och 
identifiera välfungerande och lämpliga strategier för barn med svår astma. Ett annat fynd 
hos barnen med svår astma var att flickorna rapporterade betydligt sämre livskvalitet än 
pojkarna med samma sjukdom. Detta fynd belyser att flickor och pojkar upplever sjukdom 
på olika sätt, trots att inga data i övrigt visade att flickornas sjukdom var svårare än 
pojkarnas. Snarare bör dessa fynd tas i beaktning när man utvärderar behov och effekter av 
stärkande åtgärder för skolbarn med svår astma.    
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I konklusion visar den här avhandlingen att bristande astmakontroll är vanligt bland 
skolbarn, och att barn med svår astma har betydligt sämre livskvalitet är dem med lindrig 
astma. De vanligaste faktorerna i sjukdomshistorien hos barn med bristande astmakontroll 
vid 8 och 12 år och svår astma var snuva och nästäppa samt ärftlighet för allergisk 
sjukdom.  
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